WO2017043656A1 - 標的化したdna配列の核酸塩基を特異的に変換する、グラム陽性菌のゲノム配列の変換方法、及びそれに用いる分子複合体 - Google Patents
標的化したdna配列の核酸塩基を特異的に変換する、グラム陽性菌のゲノム配列の変換方法、及びそれに用いる分子複合体 Download PDFInfo
- Publication number
- WO2017043656A1 WO2017043656A1 PCT/JP2016/076711 JP2016076711W WO2017043656A1 WO 2017043656 A1 WO2017043656 A1 WO 2017043656A1 JP 2016076711 W JP2016076711 W JP 2016076711W WO 2017043656 A1 WO2017043656 A1 WO 2017043656A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- nucleic acid
- dna
- gram
- double
- sequence
- Prior art date
Links
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 95
- 238000000034 method Methods 0.000 title claims abstract description 90
- 108091028043 Nucleic acid sequence Proteins 0.000 title claims abstract description 80
- 241000894006 Bacteria Species 0.000 title claims abstract description 40
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 37
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 37
- 108020004414 DNA Proteins 0.000 claims abstract description 143
- 239000002773 nucleotide Substances 0.000 claims abstract description 111
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 111
- 102000004190 Enzymes Human genes 0.000 claims abstract description 90
- 108090000790 Enzymes Proteins 0.000 claims abstract description 90
- 238000006243 chemical reaction Methods 0.000 claims abstract description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 60
- 102000053602 DNA Human genes 0.000 claims description 51
- 230000014509 gene expression Effects 0.000 claims description 19
- 244000005700 microbiome Species 0.000 claims description 19
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 18
- 239000011701 zinc Substances 0.000 claims description 18
- 229910052725 zinc Inorganic materials 0.000 claims description 18
- 239000013604 expression vector Substances 0.000 claims description 17
- 230000006870 function Effects 0.000 claims description 14
- 108010073062 Transcription Activator-Like Effectors Proteins 0.000 claims description 13
- 230000004048 modification Effects 0.000 claims description 12
- 238000012986 modification Methods 0.000 claims description 12
- 241000193403 Clostridium Species 0.000 claims description 11
- 241001508458 Clostridium saccharoperbutylacetonicum Species 0.000 claims description 11
- 241000555281 Brevibacillus Species 0.000 claims description 10
- 241000534630 Brevibacillus choshinensis Species 0.000 claims description 10
- 241000186226 Corynebacterium glutamicum Species 0.000 claims description 10
- 230000007018 DNA scission Effects 0.000 claims description 9
- 241000186216 Corynebacterium Species 0.000 claims description 8
- 102100026846 Cytidine deaminase Human genes 0.000 claims description 7
- 108010031325 Cytidine deaminase Proteins 0.000 claims description 7
- 230000001939 inductive effect Effects 0.000 claims description 5
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 4
- 229940088598 enzyme Drugs 0.000 description 83
- 239000013612 plasmid Substances 0.000 description 60
- 230000035772 mutation Effects 0.000 description 44
- 210000004027 cell Anatomy 0.000 description 42
- 239000013598 vector Substances 0.000 description 31
- 239000002609 medium Substances 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 26
- 230000008685 targeting Effects 0.000 description 26
- 235000018102 proteins Nutrition 0.000 description 25
- 239000013615 primer Substances 0.000 description 22
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 18
- 241000192125 Firmicutes Species 0.000 description 17
- 230000000694 effects Effects 0.000 description 16
- 108020005004 Guide RNA Proteins 0.000 description 15
- 230000005782 double-strand break Effects 0.000 description 15
- 239000012634 fragment Substances 0.000 description 15
- 150000001413 amino acids Chemical class 0.000 description 14
- 238000003780 insertion Methods 0.000 description 14
- 230000037431 insertion Effects 0.000 description 14
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 13
- 235000001014 amino acid Nutrition 0.000 description 13
- 229940024606 amino acid Drugs 0.000 description 13
- 230000000295 complement effect Effects 0.000 description 13
- 101150108780 pta gene Proteins 0.000 description 13
- 230000027455 binding Effects 0.000 description 11
- 238000012239 gene modification Methods 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 11
- 108020004705 Codon Proteins 0.000 description 10
- 101150092456 pknG gene Proteins 0.000 description 9
- 108091033409 CRISPR Proteins 0.000 description 8
- 101100243745 Schizosaccharomyces pombe (strain 972 / ATCC 24843) ptb1 gene Proteins 0.000 description 8
- 238000012300 Sequence Analysis Methods 0.000 description 8
- 101150018857 emp gene Proteins 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 238000010362 genome editing Methods 0.000 description 8
- 231100000350 mutagenesis Toxicity 0.000 description 8
- 108091079001 CRISPR RNA Proteins 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 7
- 108091028113 Trans-activating crRNA Proteins 0.000 description 7
- 229960003276 erythromycin Drugs 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000002703 mutagenesis Methods 0.000 description 7
- 108091008146 restriction endonucleases Proteins 0.000 description 7
- 108010008532 Deoxyribonuclease I Proteins 0.000 description 6
- 102000007260 Deoxyribonuclease I Human genes 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 101710163270 Nuclease Proteins 0.000 description 6
- 238000012790 confirmation Methods 0.000 description 6
- 230000005017 genetic modification Effects 0.000 description 6
- 235000013617 genetically modified food Nutrition 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 230000004568 DNA-binding Effects 0.000 description 5
- 230000001580 bacterial effect Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 238000012258 culturing Methods 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000013461 design Methods 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 101150010192 ptb1 gene Proteins 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 101000910035 Streptococcus pyogenes serotype M1 CRISPR-associated endonuclease Cas9/Csn1 Proteins 0.000 description 4
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 4
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Chemical compound NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 description 4
- 238000006481 deamination reaction Methods 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000017730 intein-mediated protein splicing Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 231100000419 toxicity Toxicity 0.000 description 4
- 230000001988 toxicity Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 108091092236 Chimeric RNA Proteins 0.000 description 3
- 241000242493 Clostridium saccharoperbutylacetonicum N1-4(HMT) Species 0.000 description 3
- 108700010070 Codon Usage Proteins 0.000 description 3
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 3
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 3
- 241000701959 Escherichia virus Lambda Species 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 239000007993 MOPS buffer Substances 0.000 description 3
- 102100039824 Pre T-cell antigen receptor alpha Human genes 0.000 description 3
- 241000235343 Saccharomycetales Species 0.000 description 3
- 102100022433 Single-stranded DNA cytosine deaminase Human genes 0.000 description 3
- 108091023040 Transcription factor Proteins 0.000 description 3
- 102000040945 Transcription factor Human genes 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 238000005520 cutting process Methods 0.000 description 3
- 238000004520 electroporation Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000012010 growth Effects 0.000 description 3
- 239000003550 marker Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 238000011144 upstream manufacturing Methods 0.000 description 3
- 239000002699 waste material Substances 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 241000186000 Bifidobacterium Species 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241001485655 Corynebacterium glutamicum ATCC 13032 Species 0.000 description 2
- 102220563802 Cysteine and histidine-rich protein 1_A23T_mutation Human genes 0.000 description 2
- 102220605874 Cytosolic arginine sensor for mTORC1 subunit 2_D10A_mutation Human genes 0.000 description 2
- 108020001019 DNA Primers Proteins 0.000 description 2
- 239000003155 DNA primer Substances 0.000 description 2
- 241000252212 Danio rerio Species 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 238000003794 Gram staining Methods 0.000 description 2
- 241000282414 Homo sapiens Species 0.000 description 2
- 241000235789 Hyperoartia Species 0.000 description 2
- 241000194036 Lactococcus Species 0.000 description 2
- 241000192132 Leuconostoc Species 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241000282577 Pan troglodytes Species 0.000 description 2
- 241000192001 Pediococcus Species 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 108020005091 Replication Origin Proteins 0.000 description 2
- 108091081021 Sense strand Proteins 0.000 description 2
- 101710143275 Single-stranded DNA cytosine deaminase Proteins 0.000 description 2
- 241000193996 Streptococcus pyogenes Species 0.000 description 2
- 241000187747 Streptomyces Species 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- 108010017070 Zinc Finger Nucleases Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 229940041514 candida albicans extract Drugs 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229940104302 cytosine Drugs 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 230000004151 fermentation Effects 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- FDGQSTZJBFJUBT-UHFFFAOYSA-N hypoxanthine Chemical compound O=C1NC=NC2=C1NC=N2 FDGQSTZJBFJUBT-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000009655 industrial fermentation Methods 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 238000001243 protein synthesis Methods 0.000 description 2
- 230000002797 proteolythic effect Effects 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 102200134465 rs80338876 Human genes 0.000 description 2
- 239000013605 shuttle vector Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 230000010474 transient expression Effects 0.000 description 2
- 229940035893 uracil Drugs 0.000 description 2
- 108700026220 vif Genes Proteins 0.000 description 2
- 239000012138 yeast extract Substances 0.000 description 2
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 description 1
- LRSASMSXMSNRBT-UHFFFAOYSA-N 5-methylcytosine Chemical compound CC1=CNC(=O)N=C1N LRSASMSXMSNRBT-UHFFFAOYSA-N 0.000 description 1
- 108010029988 AICDA (activation-induced cytidine deaminase) Proteins 0.000 description 1
- 241000186361 Actinobacteria <class> Species 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 102000055025 Adenosine deaminases Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000589158 Agrobacterium Species 0.000 description 1
- 241000962514 Alosa chrysochloris Species 0.000 description 1
- 101100365087 Arabidopsis thaliana SCRA gene Proteins 0.000 description 1
- 101100365680 Arabidopsis thaliana SGT1B gene Proteins 0.000 description 1
- 241000203069 Archaea Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193764 Brevibacillus brevis Species 0.000 description 1
- 238000010356 CRISPR-Cas9 genome editing Methods 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 208000037088 Chromosome Breakage Diseases 0.000 description 1
- 101100417900 Clostridium acetobutylicum (strain ATCC 824 / DSM 792 / JCM 1419 / LMG 5710 / VKM B-1787) rbr3A gene Proteins 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 231100001074 DNA strand break Toxicity 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- IMQLKJBTEOYOSI-UHFFFAOYSA-N Diphosphoinositol tetrakisphosphate Chemical compound OP(O)(=O)OC1C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C(OP(O)(O)=O)C1OP(O)(O)=O IMQLKJBTEOYOSI-UHFFFAOYSA-N 0.000 description 1
- 101100379225 Drosophila melanogaster cass gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 229930006677 Erythromycin A Natural products 0.000 description 1
- 101710089384 Extracellular protease Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000034951 Genetic Translocation Diseases 0.000 description 1
- 108010005440 Guanosine deaminase Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000755690 Homo sapiens Single-stranded DNA cytosine deaminase Proteins 0.000 description 1
- UGQMRVRMYYASKQ-UHFFFAOYSA-N Hypoxanthine nucleoside Natural products OC1C(O)C(CO)OC1N1C(NC=NC2=O)=C2N=C1 UGQMRVRMYYASKQ-UHFFFAOYSA-N 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 241001147746 Lactobacillus delbrueckii subsp. lactis Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241000588650 Neisseria meningitidis Species 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 241000283965 Ochotona princeps Species 0.000 description 1
- 101150034686 PDC gene Proteins 0.000 description 1
- 102000000470 PDZ domains Human genes 0.000 description 1
- 108050008994 PDZ domains Proteins 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- 241000251745 Petromyzon marinus Species 0.000 description 1
- 241000861915 Plecoglossus Species 0.000 description 1
- 241000861914 Plecoglossus altivelis Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108091008103 RNA aptamers Proteins 0.000 description 1
- 101150105073 SCR1 gene Proteins 0.000 description 1
- 102000000395 SH3 domains Human genes 0.000 description 1
- 108050008861 SH3 domains Proteins 0.000 description 1
- -1 SNR52 Proteins 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 101100134054 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) NTG1 gene Proteins 0.000 description 1
- 108020004682 Single-Stranded DNA Proteins 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194020 Streptococcus thermophilus Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 238000010459 TALEN Methods 0.000 description 1
- 108010043645 Transcription Activator-Like Effector Nucleases Proteins 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 241000589634 Xanthomonas Species 0.000 description 1
- 241000269370 Xenopus <genus> Species 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000005273 aeration Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 230000002457 bidirectional effect Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 238000000975 co-precipitation Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000001687 destabilization Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 230000009036 growth inhibition Effects 0.000 description 1
- WHWDWIHXSPCOKZ-UHFFFAOYSA-N hexahydrofarnesyl acetone Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)=O WHWDWIHXSPCOKZ-UHFFFAOYSA-N 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 238000002715 modification method Methods 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 150000002823 nitrates Chemical class 0.000 description 1
- 230000009438 off-target cleavage Effects 0.000 description 1
- 238000010397 one-hybrid screening Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 244000000003 plant pathogen Species 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000003362 replicative effect Effects 0.000 description 1
- 102200067132 rs3219484 Human genes 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000012772 sequence design Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 101150068906 snr-6 gene Proteins 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- VNOYUJKHFWYWIR-ITIYDSSPSA-N succinyl-CoA Chemical compound O[C@@H]1[C@H](OP(O)(O)=O)[C@@H](COP(O)(=O)OP(O)(=O)OCC(C)(C)[C@@H](O)C(=O)NCCC(=O)NCCSC(=O)CCC(O)=O)O[C@H]1N1C2=NC=NC(N)=C2N=C1 VNOYUJKHFWYWIR-ITIYDSSPSA-N 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/24—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Enterobacteriaceae (F), e.g. Citrobacter, Serratia, Proteus, Providencia, Morganella, Yersinia
- C07K14/245—Escherichia (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
- C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
- C12Y305/04005—Cytidine deaminase (3.5.4.5)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02E—REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION
- Y02E50/00—Technologies for the production of fuel of non-fossil origin
- Y02E50/10—Biofuels, e.g. bio-diesel
Definitions
- the present invention enables modification of nucleobases in specific regions of the Gram-positive bacterial genome without double-strand breaks in DNA (with no or single-strand breaks) and without insertion of foreign DNA fragments. And a complex of a nucleic acid sequence recognition module and a nucleobase converting enzyme used therefor.
- Gram-positive bacteria is a general term for bacteria that are stained blue-purple or purple by gram staining, and contains many useful bacteria used in traditional fermentation production and new biotechnology, such as lactic acid bacteria and actinomycetes. Unlike gram-negative bacteria such as E. coli, it does not have an outer membrane, so it has a high secretory capacity for proteins and the like, and it is suitable for the production of heterologous proteins because it does not produce endotoxins. Therefore, many attempts have been made to further improve the properties of useful bacteria by modifying the genes of Gram-positive bacteria.
- Clostridium bacteria for example, Clostridium saccharoperbutylacetonicum
- Clostridium saccharoperbutylacetonicum For the purpose of improving butanol yield, Research has been conducted to reduce by-products (acetone, ethanol, organic acids, etc.) by recombination.
- Corynebacterium glutamicum Corynebacterium glutamicum
- Corynebacterium glutamicum has been used for more than 50 years as an industrial production of amino acids for food, feed and medicine, including glutamic acid and lysine.
- Glutamic acid production can be increased by deleting the pknG gene that controls the activity of ODHC, which catalyzes the conversion of -oxoglutarate to succinyl-CoA.
- Brevibacillus choshinensis has reduced extracellular proteolytic activity and is used as a high-secretory production system for heterologous proteins, but it lacks the emp gene encoding extracellular protease. Thus, the extracellular proteolytic activity can be further reduced.
- the genetic modification in the conventional method is carried out by destroying the target gene by inserting a foreign gene using homologous recombination or deleting the genomic gene, the obtained microorganism is Corresponds to genetically modified microorganisms. Therefore, in order to ensure safety, there is a problem that equipment costs and waste disposal costs increase, and manufacturing costs increase.
- Non-patent Document 1 a method using an artificial nuclease in which a molecule having a sequence-independent DNA cutting ability and a molecule having a sequence recognition ability are combined has been proposed.
- Patent Document 1 For example, using zinc finger nuclease (ZFN) in which a zinc finger DNA binding domain and a non-specific DNA cleavage domain are linked, a host plant cell or insect cell is recombined at a target locus in DNA ( Patent Document 1), a transcriptional activator-like (TAL) effector that is a DNA binding module of the plant pathogen Xanthomonas genus and a DNA endonuclease linked to TALEN, at a site within or adjacent to a specific nucleotide sequence , A method for cleaving and modifying target genes (Patent Document 2), or a DNA sequence CRISPR (Clustered Regularly interspacedshort palindromic repeats) that functions in the acquired immune system of eubacteria and archaea, and a nuclease that plays an important role together with CRISPR CRISPR-Cas9 system combined with Cas (CRISPR-associated) protein family And a method of utilizing (P
- the genome editing techniques that have been proposed so far basically assume double-stranded DNA breaks (DSB) by nucleases. This is because genome editing technology may facilitate insertion of a foreign gene into a desired region if it can cleave a specific region in the genome based on the knowledge that DSB promotes homologous recombination. This is because it is based on the idea.
- DSB involves unexpected genome modification, there are side effects such as strong cytotoxicity and chromosomal translocation, and there are problems that the number of living cells is extremely small, or that genetic modification itself is difficult for single-cell microorganisms. It was.
- the present inventors have adopted the adoption of base conversion by a DNA base conversion reaction without insertion and / or deletion of DSB and DNA fragments.
- the base conversion reaction itself by the deamination reaction of DNA base is already known, but this is used to recognize a specific sequence of DNA, target an arbitrary site, and target DNA by base conversion of DNA base. Specific modification has not yet been realized. Therefore, deaminase that catalyzes the deamination reaction is used as an enzyme that converts such a nucleobase, and this is combined with a molecule capable of recognizing DNA sequence (nucleic acid sequence recognition module) to form three kinds of enzymes.
- CRISPR-Cas system CRISPR-mutated Cas
- RNA trans-activating crRNA: tracrRNA
- crRNA genome-specific CRISPR-RNA
- targeting sequence A DNA encoding a linked chimeric RNA molecule (guide RNA) is prepared, and on the other hand, a DNA encoding a mutant Cas protein (dCas) that has inactivated the ability to cleave both strands of double-stranded DNA (dCas) and the deaminase gene are linked.
- the present invention is as follows. [1] A method for modifying a targeted site of double-stranded DNA possessed by a Gram-positive bacterium, wherein the nucleic acid sequence recognition module specifically binds to a target nucleotide sequence in the selected double-stranded DNA; Contacting the complex bound with the nucleobase converting enzyme with the double-stranded DNA, and cutting the targeted site without cleaving at least one strand of the double-stranded DNA at the targeted site Converting or deleting one or more nucleotides into one or more other nucleotides, or inserting one or more nucleotides into the targeted site, comprising: Contacting is performed by introduction of a nucleic acid encoding the complex into the Gram-positive bacterium.
- nucleic acid sequence recognition module is selected from the group consisting of a CRISPR-Cas system in which at least one DNA cleavage ability of Cas is inactivated, a zinc finger motif, a TAL effector, and a PPR motif.
- Method [3] The method according to [1] above, wherein the nucleic acid sequence recognition module is a CRISPR-Cas system in which at least one DNA cleavage ability of Cas is inactivated.
- nucleic acid sequence recognition module is a CRISPR-Cas system in which at least one DNA cleavage ability of Cas is inactivated.
- [5] The method described in [4] above, wherein the different target nucleotide sequences are present in different genes.
- [6] The method according to any one of [1] to [5] above, wherein the nucleobase converting enzyme is deaminase.
- the deaminase is cytidine deaminase.
- [8] The method according to any one of [1] to [7] above, wherein the Gram-positive bacterium is a microorganism other than the genus Bacillus.
- the genome editing technology of the present invention since it does not involve the insertion of foreign DNA or DNA double strand breaks, it is excellent in safety. Even in cases where there is a discussion, there is a lot of possibility of a solution. For example, in industrial fermentation production using Gram-positive bacteria, it can be expected to reduce equipment costs and waste disposal costs, which is economically advantageous.
- the present invention converts the target nucleotide sequence in the double-stranded DNA and its neighboring nucleotides into other nucleotides without breaking the double-stranded DNA strand to be modified in the Gram-positive bacterial cell.
- a method for modifying the targeted site of the double-stranded DNA (hereinafter also referred to as “the method of the present invention”) is provided.
- the method of the present invention a complex in which a nucleic acid sequence recognition module that specifically binds to a target nucleotide sequence in the double-stranded DNA and a nucleobase converting enzyme are bound to each other is converted into the double-stranded DNA in a host gram-positive bacterial cell.
- the method includes a step of converting the targeted site, that is, the target nucleotide sequence and the nucleotide in the vicinity thereof into another nucleotide by contacting with the other nucleotide.
- Gram-positive bacteria that can be used in the method of the present invention are not particularly limited as long as they are bacteria that are Gram-staining-positive and vectors that can be replicated in the cells. It is preferable that it is a useful microbe utilized by new biotechnology.
- Clostridium genus Bacillus genus, Streptomyces genus (Streptmyces genus), Corynebacterium genus (Corynebacterium genus), Brevibacillus genus (Brevibacillus genus), Bifidobacterium genus (Bifidobacterium genus) ), Lactococcus spp. (Lactococcus spp.), Enterococcus spp.
- Bacteria belonging to a genus other than Bacillus are preferable. More preferred are bacteria belonging to the genus Clostridium, Brevibacillus, and Corynebacterium. Examples of bacteria belonging to the genus Clostridium include Clostridium saccharoperbutylacetonicum, etc., bacteria belonging to the genus Brevibacillus include Brevibacillus choshinensis, etc. Examples include glutamicum and the like.
- “modification” of double-stranded DNA means that a certain nucleotide (eg, dC) on the DNA strand is converted to another nucleotide (eg, dT, dA or dG) or deleted. Or a nucleotide or nucleotide sequence inserted between certain nucleotides on a DNA strand.
- the double-stranded DNA to be modified is not particularly limited as long as it is a double-stranded DNA present in the host cell, but is preferably genomic DNA.
- target site of double-stranded DNA refers to all or part of the “target nucleotide sequence” to which the nucleic acid sequence recognition module specifically recognizes and binds, or in the vicinity of the target nucleotide sequence ( 5 ′ upstream and / or 3 ′ downstream).
- target nucleotide sequence means a sequence to which a nucleic acid sequence recognition module in double-stranded DNA binds.
- the “nucleic acid sequence recognition module” means a molecule or molecular complex having the ability to specifically recognize and bind to a specific nucleotide sequence (ie, a target nucleotide sequence) on a DNA strand. Binding of the nucleic acid sequence recognition module to the target nucleotide sequence allows the nucleobase converting enzyme linked to the module to specifically act on the targeted site of double stranded DNA.
- nucleobase converting enzyme refers to a target nucleotide without cleaving a DNA strand by catalyzing a reaction for converting a substituent on a purine or pyrimidine ring of a DNA base into another group or atom. Is an enzyme capable of converting to other nucleotides.
- the “nucleic acid modifying enzyme complex” means a nucleobase converting enzyme activity having a specific nucleotide sequence recognizing ability, comprising a complex in which the nucleic acid sequence recognizing module and the nucleobase converting enzyme are linked.
- the “complex” includes not only a complex composed of a plurality of molecules, but also a complex having a nucleic acid sequence recognition module and a nucleobase converting enzyme in a single molecule, such as a fusion protein.
- the nucleobase converting enzyme used in the method of the present invention is not particularly limited as long as it can catalyze the above reaction.
- a nucleic acid / nucleotide deaminase that catalyzes a deamination reaction for converting an amino group into a carbonyl group.
- Deaminases belonging to the superfamily are included. Preferred examples include cytidine deaminase that can convert cytosine or 5-methylcytosine to uracil or thymine, adenosine deaminase that can convert adenine to hypoxanthine, and guanosine deaminase that can convert guanine to xanthine.
- cytidine deaminase include activation-induced cytidine deaminase (hereinafter also referred to as AID), which is an enzyme that introduces a mutation into an immunoglobulin gene in acquired immunity of vertebrates.
- AID activation-induced cytidine deaminase
- the origin of the nucleobase converting enzyme is not particularly limited.
- a lamprey-derived PmCDA1 Pulmyzon marinus cytosine deaminase 1
- a vertebrate eg, a mammal such as a human, pig, cow, dog, chimpanzee, etc.
- AID Activation-induced cytidine deaminase; AICDA
- birds such as chickens, amphibians such as Xenopus laevis, fish such as zebrafish, sweetfish and butcherfish
- amphibians such as Xenopus laevis
- fish such as zebrafish, sweetfish and butcherfish
- the target nucleotide sequence in the double-stranded DNA that is recognized by the nucleic acid sequence recognition module of the nucleic acid modifying enzyme complex of the present invention is not particularly limited as long as the module can specifically bind, and the target nucleotide sequence in the double-stranded DNA is not limited. It can be any sequence.
- the length of the target nucleotide sequence only needs to be sufficient for the nucleic acid sequence recognition module to specifically bind, and is 12 nucleotides or more, preferably 15 nucleotides or more, more preferably, depending on the genome size of the Gram-positive bacterium. It is 18 nucleotides or more.
- the upper limit of the length is not particularly limited, but is preferably 25 nucleotides or less, more preferably 22 nucleotides or less.
- the nucleic acid sequence recognition module of the nucleic acid modifying enzyme complex of the present invention includes, for example, a CRISPR-Cas system (CRISPR-mutated Cas) in which at least one DNA cleavage ability of Cas is inactivated, a zinc finger motif, a TAL effector, and a PPR motif
- CRISPR-mutated Cas in which at least one DNA cleavage ability of Cas is inactivated
- a zinc finger motif a TAL effector
- PPR motif a fragment containing a DNA binding domain of a protein that can specifically bind to DNA such as a restriction enzyme, transcription factor, RNA polymerase, etc., and having no DNA double-strand breakage ability
- CRISPR-mutated Cas, zinc finger motif, TAL effector, PPR motif and the like can be mentioned.
- the zinc finger motif is a linkage of 3 to 6 different zinc finger units of the Cys2His2 type (one finger recognizes about 3 bases), and can recognize a target nucleotide sequence of 9 to 18 bases.
- Zinc finger motifs are: Modular assembly method (Nat Biotechnol (2002) 20: 135-141), OPEN method (Mol Cell (2008) 31: 294-301), CoDA method (Nat Methods (2011) 8: 67-69) In addition, it can be prepared by a known method such as E. coli one-hybrid method (Nat Biotechnol (2008) 26: 695-701). The details of the production of the zinc finger motif can be referred to Patent Document 1 described above.
- the TAL effector has a repeating structure of about 34 amino acid units, and the binding stability and base specificity are determined by the 12th and 13th amino acid residues (called RVD) of one module.
- RVD 12th and 13th amino acid residues
- the PPR motif consists of 35 amino acids, and is constructed to recognize a specific nucleotide sequence by a series of PPR motifs that recognize one nucleobase.
- the 1st, 4th, and ii (-2) th amino acids of each motif Only recognize the target base. Since there is no dependence on the motif structure and there is no interference from the motifs on both sides, it is possible to produce a PPR protein specific to the target nucleotide sequence by linking the PPR motifs just like the TAL effector.
- Patent Document 4 The details of the production of the PPR motif can be referred to Patent Document 4 above.
- DNA-binding domain of these proteins is well known, so it is easy to design a fragment that contains this domain and does not have the ability to cleave DNA double strands. And can be built.
- nucleic acid sequence recognition modules can be provided as a fusion protein with the above nucleobase converting enzyme, or a protein binding domain such as SH3 domain, PDZ domain, GK domain, GB domain and their binding partners May be fused to a nucleic acid sequence recognition module and a nucleobase converting enzyme, respectively, and provided as a protein complex through the interaction between the domain and its binding partner.
- intein can be fused to the nucleic acid sequence recognition module and the nucleobase converting enzyme, and both can be linked by ligation after protein synthesis.
- the contact between the nucleic acid-modifying enzyme complex of the present invention comprising a complex (including a fusion protein) in which a nucleic acid sequence recognition module and a nucleobase converting enzyme are bound to a double-stranded DNA is the target double-stranded DNA.
- a nucleic acid encoding the complex into a Gram-positive bacterium having DNA (eg, genomic DNA). Therefore, the nucleic acid sequence recognition module and the nucleobase converting enzyme can form a complex in the host cell after translation into a protein using a binding domain or intein as a nucleic acid encoding the fusion protein. In such a form, they are prepared as nucleic acids encoding them respectively.
- the nucleic acid may be DNA or RNA.
- DNA it is preferably double-stranded DNA and is provided in the form of an expression vector placed under the control of a promoter functional in the host cell.
- RNA it is preferably a single-stranded RNA. Since the complex of the present invention in which the nucleic acid sequence recognition module and the nucleobase converting enzyme are combined does not involve DNA double strand break (DSB), genome editing with low toxicity is possible. It can be widely applied to all Gram-positive bacteria.
- DSB DNA double strand break
- a DNA encoding a nucleic acid sequence recognition module such as a zinc finger motif, a TAL effector, and a PPR motif can be obtained by any of the methods described above for each module.
- DNA encoding sequence recognition modules such as restriction enzymes, transcription factors, RNA polymerase, etc. covers the region encoding the desired part of the protein (part containing the DNA binding domain) based on the cDNA sequence information.
- oligo DNA primers can be synthesized and cloned using the total RNA or mRNA fraction prepared from cells producing the protein as a template and amplified by RT-PCR.
- an oligo DNA primer is synthesized based on the cDNA sequence information of the enzyme used, and the total RNA or mRNA fraction prepared from the cell producing the enzyme is used as a template. It can be cloned by amplification by RT-PCR.
- DNA encoding lamprey PmCDA1 is designed based on the cDNA sequence (accession No. EF094822) registered in the NCBI database, and appropriate primers are designed upstream and downstream of CDS. Can be cloned by RT-PCR.
- DNA encoding human AID is designed based on the cDNA sequence (accession No.
- AID homologues derived from other vertebrates also include known cDNA sequence information (eg, pig (accession No. CU582981), cattle (accession No. NM_110138682), dog (accession No. NM_001003380), chimpanzee (accession No. NM_001071809), Based on chicken (accession No. NM_001243222), Xenopus (accession No. NM_001095712), zebrafish (accession No.
- AAI62573 (accession No. AB619797), butterfly (accession No. NM_001200185), etc.) It can be cloned in the same way.
- the cloned DNA can be digested as is, or if desired, with restriction enzymes, or after adding an appropriate linker, and then ligated with the DNA encoding the nucleic acid sequence recognition module to prepare the DNA encoding the fusion protein. Can do.
- a DNA encoding a nucleic acid sequence recognition module and a DNA encoding a nucleobase converting enzyme are each fused with a DNA encoding a binding domain or its binding partner, or both DNAs are fused with a DNA encoding a separated intein.
- a complex may be formed after the nucleic acid sequence recognition module and the nucleobase converting enzyme are translated in the host cell.
- a linker can be linked to an appropriate position of one or both DNAs as desired.
- DNA encoding nucleic acid sequence recognition modules and DNA encoding nucleobase converting enzymes chemically synthesize DNA strands or synthesize partially overlapping oligo DNA short strands using PCR or Gibson Assembly methods. It is also possible to construct a DNA that encodes the full length by using and connecting.
- the advantage of constructing full-length DNA by chemical synthesis or in combination with PCR method or Gibson Assembly method is that the codon used can be designed over the entire CDS according to the host into which the DNA is introduced. In the expression of heterologous DNA, an increase in protein expression level can be expected by converting the DNA sequence into a codon frequently used in the host organism.
- Data on the frequency of codon usage in the host to be used is, for example, the genetic code usage frequency database (http://www.kazusa.or.jp/codon/index.html) published on the Kazusa DNA Research Institute website. ) May be used, or references describing codon usage in each host may be consulted.
- the obtained data and the DNA sequence to be introduced and converting the codon used in the DNA sequence that is not frequently used in the host into a codon that encodes the same amino acid and is frequently used Good.
- An expression vector containing a DNA encoding a nucleic acid sequence recognition module and / or a nucleobase converting enzyme can be produced, for example, by ligating the DNA downstream of a promoter in an appropriate expression vector.
- a shuttle vector of Escherichia coli and Clostridium is convenient.
- pKNT19 derived from pIM13 (Journal of General Microbiology, 138, 1371-1378 (1992)
- Examples of the vector that can replicate in the genus Brevibacillus include pUB110 derived from Brevibacillus brevis, and the vector that can replicate in the genus Corynebacterium includes the pCG100-pHSG398 hybrid plasmid derived from Corynebacterium glutamicum. Furthermore, examples of vectors that can replicate in the genus Lactobacillus include pLAB1000 derived from Lactobacillus lactis.
- the promoter may be any promoter as long as it is appropriate for the host used for gene expression. In conventional methods involving DSB, the viability of host cells may be significantly reduced due to toxicity, so it is desirable to use an inducible promoter to increase the number of cells by the start of induction. Since sufficient cell growth can be obtained even if the enzyme complex is expressed, a constitutive promoter can also be used without limitation.
- the expression vector can contain a terminator, a repressor, a drug resistance gene, a selection marker such as an auxotrophic complementary gene, a replication origin that can function in Escherichia coli, and the like, if desired.
- RNA encoding the nucleic acid sequence recognition module and / or the nucleobase converting enzyme is, for example, a per se known in vitro transcription system using a vector encoding the DNA encoding the nucleic acid sequence recognition module and / or the nucleobase converting enzyme as a template. Can be prepared by transcription into mRNA.
- nucleic acid sequence recognition module By introducing an expression vector containing a nucleic acid sequence recognition module and / or a DNA encoding a nucleobase converting enzyme into a host cell and culturing the host cell, the complex of the nucleic acid sequence recognition module and the nucleobase converting enzyme is converted into a cell. Can be expressed within.
- the expression vector may be introduced by a known method (eg, lysozyme method, competent method, PEG method, CaCl 2 coprecipitation method, electroporation method, microinjection method, particle gun method, lipofection method, Agrobacterium method, etc.).
- a known method eg, lysozyme method, competent method, PEG method, CaCl 2 coprecipitation method, electroporation method, microinjection method, particle gun method, lipofection method, Agrobacterium method, etc.
- a liquid medium is preferable as the medium used for the culture.
- a culture medium contains a carbon source, a nitrogen source, an inorganic substance, etc. which are required for the growth of a transformant.
- the carbon source include glucose, dextrin, soluble starch, and sucrose
- examples of the nitrogen source include ammonium salts, nitrates, corn steep liquor, peptone, casein, meat extract, soybean meal, Inorganic or organic substances such as potato extract
- examples of inorganic substances include calcium chloride, sodium dihydrogen phosphate, magnesium chloride, and the like.
- yeast extract vitamins, growth promoting factors and the like may be added to the medium.
- the pH of the medium is preferably about 5 to about 8.
- Gram positive bacteria are usually cultured at about 30 to about 40 ° C. If necessary, aeration or agitation may be performed.
- a complex of a nucleic acid sequence recognition module and a nucleobase converting enzyme that is, a nucleic acid modifying enzyme complex can be expressed in a cell.
- RNA encoding a nucleic acid sequence recognition module and / or nucleobase converting enzyme into Gram-positive bacteria can be performed by a method known per se.
- RNA can be introduced once or repeatedly several times (for example, 2 to 5 times) at an appropriate interval.
- the nucleic acid sequence recognition module When a complex of a nucleic acid sequence recognition module and a nucleobase converting enzyme is expressed from an expression vector or RNA molecule introduced into a cell, the nucleic acid sequence recognition module is contained in the target double-stranded DNA (eg, genomic DNA).
- a target nucleotide sequence (all or a part of the target nucleotide sequence or its vicinity) is detected by the action of a nucleobase converting enzyme that specifically recognizes and binds to the target nucleotide sequence and is linked to the nucleic acid sequence recognition module.
- Base conversion occurs in the sense strand or antisense strand, resulting in mismatch in the double-stranded DNA (for example, when cytidine deaminase such as PmCDA1 or AID is used as the nucleobase converting enzyme, the sense strand or Cytosine on the antisense strand is converted to uracil, resulting in a U: G or G: U mismatch).
- This mismatch is not repaired correctly, and the opposite strand base is repaired to pair with the converted strand base (TA or AT in the above example), or replaced with another nucleotide during repair.
- U ⁇ A, G or deletions or insertions of 1 to several tens of bases are introduced to introduce various mutations.
- Zinc finger motifs are not efficient in producing zinc fingers that specifically bind to the target nucleotide sequence, and the selection of zinc fingers with high binding specificity is complicated, so many zinc finger motifs that actually function are created. It's not easy. TAL effectors and PPR motifs have a higher degree of freedom in target nucleic acid sequence recognition than zinc finger motifs, but it is necessary to design and construct a huge protein each time depending on the target nucleotide sequence, which is problematic in terms of efficiency. Remains. In contrast, the CRISPR-Cas system recognizes the target double-stranded DNA sequence with a guide RNA complementary to the target nucleotide sequence, so it can synthesize oligo DNA that can specifically hybridize with the target nucleotide sequence.
- CRISPR-Cas system in which at least one DNA cleavage ability of Cas is inactivated is used as the nucleic acid sequence recognition module.
- the nucleic acid sequence recognition module of the present invention using CRISPR-mutated Cas includes CRISPR-RNA (crRNA) containing a sequence complementary to the target nucleotide sequence, and trans-activating RNA (tracrRNA) necessary for recruitment of mutant Cas protein. It is provided as a complex of a chimeric RNA (guide RNA) consisting of mutated Cas protein.
- the Cas protein used in the present invention is not particularly limited as long as it forms a complex with the guide RNA and can recognize and bind to the target nucleotide sequence in the target gene and the adjacent protospacer adjacent motif (PAM). Cas9 is preferable.
- Cas9 examples include Cas9 derived from Streptococcus pyogenes (Streptococcus pyogenes) (SpCas9; PAM sequence NGG (N is A, G, T, or C; the same applies hereinafter)), Cas9 derived from Streptococcus thermophilus (StCas9; PAM sequence NNAGAAW), Cas9 derived from Neisseria meningitidis (MmCas9; PAM sequence NNNNGATT), and the like, but are not limited thereto. SpCas9, which is less constrained by PAM, is preferred (substantially 2 bases and can be theoretically targeted almost anywhere on the genome).
- the mutant Cas used in the present invention is one in which the ability to cleave both strands of the double-stranded DNA of Cas protein is inactivated, and one having the nickase activity in which only one strand is cleaved is inactivated. It can be used.
- the 10th Asp residue is converted to an Ala residue
- the D10A mutant lacking the ability to cleave the opposite strand that forms a complementary strand with the guide RNA, or the 840th His residue is The H840A mutant lacking the ability to cleave the guide RNA and the complementary strand converted at the Ala residue, or a double mutant thereof, can be used, but other mutant Cass can be used as well.
- the nucleobase converting enzyme is provided as a complex with the mutant Cas by the same method as that for linking with the zinc finger or the like.
- the nucleobase converting enzyme and the mutant Cas can be bound by using RNA-scaffold by the RNA-aptamer MS2F6, PP7, etc. and their binding protein.
- the targeting sequence in the guide RNA forms a complementary strand with the target nucleotide sequence, and the mutant Cas is recruited to the subsequent tracrRNA to recognize PAM, but one or both of the DNAs cannot be cleaved, and the mutant Cas Due to the action of the linked nucleobase converting enzyme, base conversion occurs at the targeted site (adjustable within a range of several hundred bases including all or part of the target nucleotide sequence), and mismatches in double-stranded DNA Occurs.
- the opposite strand base is repaired to pair with the converted strand base, converted to another nucleotide during the repair, or a deletion of one to several tens of bases Alternatively, various mutations are introduced by causing insertion.
- nucleic acid sequence recognition module Even when CRISPR-mutated Cas is used as a nucleic acid sequence recognition module, as in the case of using zinc fingers or the like as a nucleic acid sequence recognition module, the nucleic acid sequence recognition module and the nucleobase converting enzyme are in the form of nucleic acids that encode them, Introduced into Gram-positive bacteria with the desired double-stranded DNA.
- the DNA encoding Cas can be cloned from the cell producing the enzyme by the same method as described above for the DNA encoding the nucleobase converting enzyme.
- the mutant Cas is obtained by using the site-directed mutagenesis method known per se to the cloned Cas-encoding DNA, and the amino acid residue at the site important for DNA cleavage activity (for example, in the case of Cas9, the 10th position). Asp residues and the 840th His residue, but not limited thereto) can be obtained by introducing mutations so that they are converted with other amino acids.
- the DNA encoding the mutant Cas is a method similar to that described above for the DNA encoding the nucleic acid sequence recognition module and the DNA encoding the nucleobase converting enzyme, in combination with chemical synthesis or PCR method or Gibson Assembly method, It can also be constructed as DNA with codon usage suitable for expression in the host cell used.
- the DNA encoding the mutant Cas and the DNA encoding the nucleobase converting enzyme may be linked so as to be expressed as a fusion protein or expressed separately using a binding domain, intein, etc. Alternatively, it may be designed to form a complex in the host cell via protein ligation.
- the obtained DNA encoding the mutant Cas and / or nucleobase converting enzyme can be inserted downstream of the promoter of the expression vector as described above, depending on the host.
- the DNA encoding the guide RNA includes a crRNA sequence containing a nucleotide sequence complementary to the “targeted strand” of the target nucleotide sequence (also referred to as a “targeting sequence”), and a known An oligo DNA sequence in which a tracrRNA sequence (for example, gttttagagctagaaatagcaagttaaaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtggtgcttttt; SEQ ID NO: 1) is designed can be designed and chemically synthesized using a DNA / RNA synthesizer.
- a tracrRNA sequence for example, gttttagagctagaaatagcaagttaaaataaggctagtccgttatcaacttgaaaaagtggcaccgagtcggtggtgcttttt
- the “target strand” means the strand that hybridizes with the crRNA of the target nucleotide sequence, and the strand that becomes a single strand by hybridization of the target strand with the crRNA at the opposite strand is referred to as the “non-target strand”. (Non-targeted strand) ”.
- the nucleobase conversion reaction usually occurs on a non-target strand that is single-stranded, so when expressing the target nucleotide sequence on one strand (for example, when expressing a PAM sequence) Or when representing the positional relationship between the target nucleotide sequence and PAM), it is represented by the sequence of the non-target strand.
- the length of the targeting sequence is not particularly limited as long as it can specifically bind to the target nucleotide sequence, and is, for example, 15 to 30 nucleotides, preferably 18 to 25 nucleotides. Selection of the target nucleotide sequence is limited by the presence of PAM adjacent 3 ′ to the sequence, but according to the system of the present invention combining CRISPR-mutated Cas and cytidine deaminase, the length of the target nucleotide sequence Regardless of the above, since there is a regularity that mutations are easily introduced into C located within 7 nucleotides from the 5 'end, the length of the target nucleotide sequence (targeting sequence that is its complementary strand) should be selected appropriately. Can shift the site of the base into which the mutation can be introduced. Thereby, the restriction
- Targeting sequence design for example, using a public guide RNA design website (CRISPR Design Tool, CRISPRdirect, etc.), a 20mer sequence adjacent to PAM (eg, NGG) 3 'from the CDS sequence of the target gene Can be obtained by selecting a sequence that causes an amino acid change in the protein encoded by the target gene when C within 7 nucleotides from the 5 ′ end is converted to T. Furthermore, when the length of the targeting sequence is changed, for example, in the range of 18 to 25 nucleotides, similarly, a sequence in which C that causes an amino acid change by base conversion to T is present within 7 nucleotides from the 5 ′ end. Select.
- CRISPR Design Tool CRISPRdirect, etc.
- a candidate sequence with a small number of off-target sites in the target Gram-positive bacterium genome can be used as a targeting sequence.
- CRISPR Design Tool and CRISPRdirect do not currently have a function to search off-target sites of Gram-positive bacterial genomes. For example, 8 to 12 nucleotides on the 3 'side of candidate sequences (seeds with high target nucleotide sequence discrimination ability) With regard to (sequence), an off-target site can be searched by performing a Blast search on the Gram-positive bacterial genome serving as a host.
- a DNA encoding a guide RNA can also be inserted into an expression vector similar to the above depending on the host, but as a promoter, a pol III promoter (eg, SNR6, SNR52, SCR1, RPR1, U6, H1 it is preferred to use a promoter) and a terminator (e.g., T 6 sequences).
- a pol III promoter eg, SNR6, SNR52, SCR1, RPR1, U6, H1 it is preferred to use a promoter
- a terminator e.g., T 6 sequences.
- RNA encoding the mutant Cas and / or nucleobase converting enzyme is, for example, converted to mRNA in a per se known in vitro transcription system using the vector encoding the DNA encoding the mutant Cas and / or nucleobase converting enzyme as a template. It can be prepared by transferring. Guide RNA (crRNA-tracrRNA) is designed using an RNA / RNA synthesizer, which is designed as an oligo RNA sequence linking a sequence complementary to the target strand of the target nucleotide sequence and a known tracrRNA sequence. Can be synthesized.
- DNA or RNA encoding mutant Cas and / or nucleobase converting enzyme may be introduced into Gram-positive bacteria. it can.
- DSBs DNA double-strand breaks
- off-target breaks random chromosome breaks
- mutation is introduced not by DNA cleavage but by conversion reaction of a substituent on a DNA base (particularly deamination reaction), so that the toxicity can be greatly reduced.
- the double-stranded DNA is cleaved at a site other than the targeted site (adjustable within a range of several hundred bases including all or part of the target nucleotide sequence).
- the modification of the double-stranded DNA of the present invention was selected. It does not involve DNA strand breaks not only at the targeted site of double-stranded DNA but also at other sites.
- double mutant Cas9 is used, but the present inventors use other microorganisms such as budding yeast and Escherichia coli as a host, and as mutant Cas, one of the double-stranded DNAs.
- Cas having nickase activity capable of cleaving only one strand the efficiency of mutagenesis is increased compared to the case using mutant Cas that cannot cleave both strands.
- a protein with nickase activity is further ligated to cleave only a single strand of DNA near the target nucleotide sequence, avoiding strong toxicity due to DSB, while introducing mutation efficiency Has been found to be possible to improve.
- the mutation sites were concentrated near the center of the target nucleotide sequence, whereas on the other hand, the number of It has also been confirmed that various mutations are randomly introduced into a region spanning 100 bases. Therefore, also in the present invention, by selecting a strand that nickase cleaves, a mutation is introduced into a specific nucleotide or nucleotide region of a double-stranded DNA possessed by a Gram-positive bacterium, or within a relatively wide range. Various mutations can be introduced at random, and can be selected according to the purpose.
- the present inventors have also shown that by introducing a sequence recognition module for a plurality of adjacent target nucleotide sequences and using them simultaneously, the efficiency of mutagenesis is significantly increased compared to targeting a single nucleotide sequence. , Using budding yeast.
- the effect is similar to the case where both of the target nucleotide sequences overlap, and even when they are separated by about 600 bp, mutation induction is realized in the same manner. It can occur either when the target nucleotide sequence is in the same direction (the target strand is the same strand) or opposite (both strands of double-stranded DNA are the target strand).
- the present invention introduces mutations in almost all cells in which the nucleic acid-modifying enzyme complex of the present invention is expressed if an appropriate target nucleotide sequence is selected. This is confirmed using budding yeast. Therefore, selection marker gene insertion and selection, which is essential in conventional genome editing, are not necessary. This dramatically simplifies genetic manipulation and at the same time eliminates the use of foreign DNA recombinant microorganisms, greatly expanding the applicability of useful microorganisms such as molecular breeding.
- the genomic sequence modification method of the present invention can be modified with a plurality of DNA regions at completely different positions as targets.
- each of the different specific nucleotide sequences (which may be in one target gene or in two or more different target genes) specifically binds.
- Two or more nucleic acid sequence recognition modules can be used.
- each one of these nucleic acid sequence recognition modules and the nucleobase converting enzyme form a nucleic acid modifying enzyme complex.
- a common nucleobase converting enzyme can be used.
- a complex of Cas protein and nucleobase converting enzyme including a fusion protein
- a different target is used as a guide RNA (crRNA-tracrRNA).
- Two or more kinds of chimeric RNAs each of two or more crRNAs each forming a complementary strand with the nucleotide sequence and tracrRNA can be prepared and used.
- a zinc finger motif, a TAL effector, or the like is used as the nucleic acid sequence recognition module, for example, a nucleobase converting enzyme can be fused to each nucleic acid sequence recognition module that specifically binds to a different target nucleotide.
- an expression vector containing DNA encoding the nucleic acid modifying enzyme complex, or RNA encoding the nucleic acid modifying enzyme complex is used.
- an expression vector capable of autonomous replication in the host cell, but since the plasmid etc. are foreign DNA, after successful mutagenesis, It is preferred that it be removed quickly.
- the previously introduced plasmid should be replaced before the subsequent plasmid introduction. Need to be removed. Therefore, although it varies depending on the type of the host cell, etc., for example, after 6 hours to 2 days have passed since the introduction of the expression vector, the plasmid introduced from the host cell is removed using various plasmid removal methods well known in the art. It is desirable.
- an expression vector that does not have autonomous replication ability in the host cell for example, a replication origin that functions in the host cell and / or a protein necessary for replication
- RNA or the like which lacks a gene encoding a gene
- the gene essential for host cell survival is used as the target gene.
- direct editing has been difficult until now (adverse effects such as impaired growth of the host, destabilization of mutagenesis efficiency, mutation to a site different from the target).
- the nucleobase conversion reaction takes place at a desired time, and the nucleic acid-modifying enzyme complex of the present invention is temporarily transferred into the host cell only for a period necessary for fixing the modification of the targeted site.
- the time required for the nucleobase conversion reaction to occur and the modification of the targeted site to be fixed varies depending on the type of host cell, culture conditions, etc., but usually 2 to 20 generations are considered necessary. .
- a person skilled in the art can appropriately determine a suitable expression induction period based on the doubling time of the host cell under the culture conditions to be used.
- the expression induction period of the nucleic acid encoding the nucleic acid-modifying enzyme complex of the present invention is extended beyond the above-mentioned "period necessary for fixing the modification of the targeted site" within a range that does not cause a side effect on the host cell. May be.
- a nucleic acid encoding the nucleic acid modifying enzyme complex in the CRISPR-Cas system, a guide RNA is encoded).
- the “form capable of controlling the expression period” include a nucleic acid encoding the nucleic acid-modifying enzyme complex of the present invention under the control of an inducible regulatory region.
- the “inducible regulatory region” is not particularly limited, and examples thereof include an operon of a temperature sensitive (ts) mutation repressor and an operator controlled thereby.
- the ts mutation repressor include, but are not limited to, a ts mutant of a cI repressor derived from ⁇ phage.
- ⁇ phage cI repressor ts
- binding to the operator is suppressed at 30 ° C or lower (eg, 28 ° C), but downstream gene expression is suppressed, but at a high temperature of 37 ° C or higher (eg, 42 ° C), the operator Gene expression is induced to dissociate from.
- a host cell into which a nucleic acid encoding a nucleic acid-modifying enzyme complex has been introduced is usually cultured at 30 ° C. or lower, and the temperature is raised to 37 ° C. or higher at an appropriate time, followed by culturing for a certain period of time.
- the period during which the expression of the target gene is suppressed can be minimized by quickly returning it to 30 ° C. or lower, and targets the essential gene for the host cell. Even in this case, editing can be performed efficiently while suppressing side effects.
- a temperature-sensitive mutation for example, by mounting a temperature-sensitive mutant of a protein necessary for autonomous replication of the vector on a vector containing a DNA encoding the nucleic acid-modifying enzyme complex of the present invention, the nucleic acid-modifying enzyme After the complex is expressed, autonomous replication cannot be performed immediately, and the vector naturally falls off with cell division. Therefore, by using together with the cI repressor (ts) of the above-mentioned ⁇ phage, transient expression of the nucleic acid modifying enzyme complex of the present invention and plasmid removal can be performed simultaneously.
- Example 1 Genetic modification in Clostridium saccharoperbutylacetonicum
- Construction of disruption vector plasmid-introduction of modified CRISPR into pKNT19 Plasmid pKNT19 replicable in Escherichia coli and Clostridium microorganisms was digested with restriction enzymes BamHI and KpnI
- the following necessary gene sequences were inserted to construct a disruption vector plasmid.
- D10A and H840A amino acid mutations were introduced into the Streptococcus pyogens Cas9 gene containing a bidirectional promoter region (dCas9), and a construct expressed as a fusion protein with PmCDA1 via a linker sequence was constructed.
- a plasmid full-length nucleotide sequence is shown in SEQ ID NO: 4 on which a chimeric gRNA encoding a sequence complementary to each target nucleotide sequence (targeting sequence) in the pika gene of Nicham (SEQ ID NOs: 2 and 3) is shown. Twenty portions (each targeting sequence is inserted into nucleotide number 5560-5579) were created (FIG. 1).
- TYA medium As preculture, 0.5 mL of glycerol stocks of C. saccharoperbutylacetonicum ATCC27021 strain and ATCC27021 ⁇ ptb1 strain were inoculated into 5 mL of TYA medium and cultured at 30 ° C for 24 hours.
- the composition of TYA medium is shown in Table 2.
- the fermentation broth was centrifuged to remove the supernatant, and 10 ml of ice-cooled 65 mm MOPS buffer (pH 6.5) was added and resuspended by pipetting and centrifuged. It was. Washing with MOPS buffer was repeated twice. After removing the MOPS buffer by centrifugation, the cell pellet was resuspended with 100 ⁇ L of 0.3 ⁇ M sucrose that had been ice-cooled to obtain a competent cell.
- 50 ⁇ L of competent cells were taken into an Eppendorf tube and mixed with 1 ⁇ g of plasmid.
- the sample was placed in an ice-cooled electroporation cell and applied in Exponential-dcay mode, 2.5 kV / cm, 25 ⁇ F, 350 ⁇ .
- the electroporation apparatus used was Gene pulser xcell (Bio-rad). Thereafter, the entire amount was inoculated into 5 mL TYA medium, and cultured for recovery for 2 hours at 30 ° C.
- the recovery medium is applied to a MASS solid medium containing 10 ppm of erythromycin, cultured at 30 ° C for several days, and then selected from the colonies that emerged to obtain a strain that has become plasmid-introduced and has become erythromycin resistant. did.
- the plasmid was retained in the obtained strain.
- Each colony was inoculated into a TIA medium containing 10 ppm of erythromycin, and the plasmid-specific region was amplified by PCR using a culture solution derived from the grown transformant colony as a template. From the analysis of the amplified product by electrophoresis The presence or absence of plasmid retention was confirmed.
- This single colony was picked up with 8 colonies of 11757 / ATCC27021 ⁇ ptb1 strain and 1269 + AatII / ATCC27021 strain, and 16 colonies of 1269 + AatII / ATCC27021 ⁇ ptb1, and the entire pta gene on the genome was amplified using this as a template.
- PCR composition (1 sample) 2 ⁇ KODFX buffer 25 ⁇ L 2 mM dNTPS 10 ⁇ L 20 ⁇ M F primer 0.75 ⁇ L (NS-150414-i02) 20 ⁇ M R primer 0.75 ⁇ L (NS-150304-i04) DW 11.5 ⁇ L KODFX 1 ⁇ L
- NS-150414-i02 array 5'-GCCCTTTATGAAAGGGATTATATTCAG-3 '(SEQ ID NO: 7)
- NS-150304-i04 array 5'-GCTTGTACAGCAGTTAATGCAAC-3 '(SEQ ID NO: 8)
- the PCR product was purified by Wizard (registered trademark) SV-Gel-and-PCR-Clean-Up System, and a sequence reaction was performed using the purified product as a template.
- Sequence reaction composition (1 sample) Terminator Ready Reaction Mix 1 ⁇ L 5 ⁇ Sequencing buffer 3.5 ⁇ L 3.2pmol primer 1 ⁇ L Template DNA 0.35 ⁇ L DW 14.15 ⁇ L Template DNA and primer were combined as follows. 1269 + AatII holding strain F side NS-150414-i02 / R side NS-150304-i04 11753 holding shares F side NS-150525-i01 / R side NS-150304-i04
- NS-150525-i01 sequence 5'-GGTGTTACAGGAAATGTTGCAG-3 '(SEQ ID NO: 9)
- the above composition was subjected to PCR under the following conditions. 96 °C 1 min 96 °C 10 sec ⁇ 50 °C 5 sec ⁇ 60 °C 4 min ⁇ 25 cycles 10 °C hold After completion of the reaction, the sequence of the reaction product was analyzed with a DNA sequencer ABI PRISM3101.
- Table 3 shows the 916th to 935th DNA sequences of the pta gene among the sequence analysis results of colonies derived from 11757 / ATCC27021 ⁇ ptb1.
- Example 2 Genetic modification in Corynebacterium glutamicum (1) Preparation of shuttle vector A pCG100 plasmid derived from C. glutamicum ATCC13058 strain was obtained by the method described in Example 1 of WO 2007/013695. In order to perform ligation with pHSG398, pCG100 was cleaved with the restriction enzyme BglII, and pHSG398 was cleaved with BamHI and dephosphorylated to prevent self-ligation. pCG100 (cut with BglII) and pHSG398 (cut with BamHI) were ligated and introduced into E. coli.
- PCR primer F atgaaggataatgaagatttcgatccagattcac (SEQ ID NO: 41)
- PCR primer R gaaccaactcagtggccgc (SEQ ID NO: 42)
- PCR primer F cagcaaccgaagctgttgcc (SEQ ID NO: 72)
- PCR primer R gccatcagcaactgggcg SEQ ID NO: 73
- Example 3 Genetic modification in Brevibacillus choshinensis (1) Preparation of emp gene modified plasmid B. pBIC1 plasmid that can be used in choshinensis was cleaved with restriction enzymes XhoI and HindIII, and the necessary modified CRISPR DNA fragment ( A modified CRISPR plasmid that functions by transforming B. choshinensis was prepared by inserting the above HindIII-XhoI fragment of about 6 kbp of SEQ ID NO: 18. B. Targeting sequences (Table 7) for modifying the emp gene of Chou sinensis (SEQ ID NOs: 43 and 44) were designed, and Nos. 5, 6 and 7 were designated as targeting sequence insertion sites (n 20 ) (nucleotide number 8773-8792 of SEQ ID NO: 18) to prepare an emp gene-modified plasmid.
- ⁇ Culture medium MTNm plate Add to MT medium to give neomycin 50 ppm MT medium glucose 10 g / L Phyton peptone 10 g / L Erlich Skipjack Extract 5 g / L Powdered yeast extract S 2 g / L FeSO 4 ⁇ 7H 2 O 10 mg / L MnSO 4 ⁇ 4H 2 O 10 mg / L ZnSO 4 ⁇ 7H 2 O 1 mg / L Adjust to pH 7.0
- PCR primer F gggacatgattcgccggttg SEQ ID NO: 59
- PCR primer R gcgtccatcgtagtaccagatc SEQ ID NO: 60
- Example 4 Genetic Modification in Clostridium saccharoperbutylacetonicum (2)
- Creation of a host for multiple gene disruption DNA sequence conversion of the pta gene of ATCC27021 strain was performed using 11757 / ATCC27021, which is the 11757 holding strain prepared in Example 1 (2).
- the obtained mutants R311K (the 932th base G of the pta gene was changed to A) and G312R (the 934th base G of the pta gene were changed to A)
- Plasmid 11757 was removed from (modified).
- Example 1 (3) Methods of DNA sequence conversion and sequence analysis of the pta gene were performed in the same manner as in Example 1 (3) using 11757 / ATCC27021, which is the 11757 holding strain prepared in Example 1 (2).
- Mutant strains R311K (the 932th base G of the pta gene was changed to A) and G312R (the 934th base G of the pta gene was changed to A) strains obtained as a result of the sequence analysis were stored in TYA medium without antibiotics. After culturing in step 1, dilute and apply to a solid medium, and use the grown single colony as a template to confirm the presence or absence of plasmid retention by the method shown in Example 1 (2). Selected.
- PCR composition (1 sample) 2 ⁇ KODFX buffer 25 ⁇ L 2 mM dNTPS 10 ⁇ L 20 ⁇ M F primer 0.75 ⁇ L (NS-150410-i01) 20 ⁇ M R primer 0.75 ⁇ L (NS-150410-i02) DW 11.5 ⁇ L KODFX 1 ⁇ L
- NS-150410-i01 array 5'-CCGATAGCTAAGCCTATTGAG-3 '(SEQ ID NO: 61)
- NS-150410-i02 array 5'-TCATCCTGTGGAGCTTAGTAG-3 '(SEQ ID NO: 62)
- PCR products were electrophoresed, and colonies without amplified plasmid-specific regions derived from each mutant strain (R311K and G312R) were designated as 11757-dropped strains ATCC27021R311K and ATCC27021G312R, respectively.
- 64G> A introduces a mutation of 64G> A and / or 66G> A and / or 67G> A into the target gene ptb1, and introduces a mutation of V22I or V22 and / or A23T at the amino acid level.
- 442C> T is a disruption vector that mutates P148 to L or S.
- Proline is an imino acid and is known to locally reduce the degree of freedom of the protein. When this is changed to leucine, it becomes difficult to maintain the structure, and a decrease or disappearance of activity is expected.
- 655G> A is a disruption vector to mutate A219 to T, and 745G> A to mutate A249 to T.
- Non-polar alanine with a small side chain is mutated to threonine with a polar and bulky side chain, which changes the structure of the PTB1 protein and is expected to decrease or disappear.
- 745G> A can also introduce a 751G> A mutation (mutating V251 to I).
- the single colony was picked and the full length of the ptb1 gene on the genome was amplified using this single colony.
- the PCR composition and conditions were in accordance with Example 1 (3), and NS-150819-i01 and NS-150819-i02 for ptb1 were used only as primers.
- NS-150819-i01 sequence 5'-GCAAGAAATGAGCAAAAACTTTGACG-3 '(SEQ ID NO: 69)
- NS-150819-i02 sequence 5'-GCTGCAACTAATGCTGCTAAAGC-3 '(SEQ ID NO: 70)
- PCR product was purified by Wizard (registered trademark) SV Gel and PCR Clean-Up System, and a sequence reaction was performed using the purified product as a template.
- the sequence reaction composition and conditions were in accordance with Example 1 (3).
- NS-150819-i01 (SEQ ID NO: 69) was used for the 64G> A-bearing strain with only the primer, and NS-150324-i01 was used for the others.
- Mutations of 442C> T and / or 443C> T resulted in strains that became P148L or P148S as PTB1 protein.
- strains with mutation introduction of 655G> A were obtained. Due to the mutation of 655G> A, a strain having A219T as PTB1 protein was obtained.
- strains with mutation introduction of 745G> A and / or 751G> A were obtained.
- Mutations of 745G> A and / or 751G> A resulted in strains that became A249T and / or V251I as PTB1 proteins.
- site-specific mutation can be safely introduced into any Gram-positive bacterium without insertion of foreign DNA or DNA double-strand break. Since the genetically modified strains obtained in this way are not considered to be genetically modified microorganisms, in industrial fermentation production using Gram-positive bacteria, it can be expected to reduce equipment costs and waste disposal costs, and it is possible to reduce manufacturing costs This is extremely useful.
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Crystallography & Structural Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
また、コリネバクテリウム・グルタミカム(Corynebacterium glutamicum)は、グルタミン酸やリジンをはじめとする、食品用、飼料用、医薬用のアミノ酸の工業生産菌として50年以上にわたり使用されているが、TCAサイクルの2-オキソグルタル酸からサクシニル-CoAへの変換を触媒するODHCの活性を制御するpknG遺伝子を欠損させることにより、グルタミン酸の生産を増大させることができる。
さらに、ブレビバチルス・チョウシネンシス(Brevibacillus choshinensis)は細胞外のタンパク質分解活性が低減されており、異種タンパク質の高分泌生産系として利用されているが、細胞外プロテアーゼをコードするemp遺伝子を欠損させることにより、さらに細胞外のタンパク質分解活性が低減することができる。
例えば、ジンクフィンガーDNA結合ドメインと非特異的なDNA切断ドメインとを連結した、ジンクフィンガーヌクレアーゼ(ZFN)を用い、宿主の植物細胞または昆虫細胞にDNA中の標的遺伝子座において組換えを行う方法(特許文献1)、植物病原菌キサントモナス属が有するDNA結合モジュールである転写活性化因子様(TAL)エフェクターと、DNAエンドヌクレアーゼとを連結したTALENを用いて、特定のヌクレオチド配列内又はそれに隣接する部位で、標的遺伝子を切断・修飾する方法(特許文献2)、あるいは、真正細菌や古細菌が持つ獲得免疫システムで機能するDNA配列CRISPR(Clustered Regularly interspacedshort palindromic repeats)と、CRISPRとともに重要な働きを持つヌクレアーゼCas(CRISPR-associated)タンパク質ファミリーとを組み合わせたCRISPR-Cas9システムを利用する方法(特許文献3)などが報告されている。さらには、35個のアミノ酸からなり1個の核酸塩基を認識するPPRモチーフの連続によって、特定のヌクレオチド配列を認識するように構成されたPPRタンパク質と、ヌクレアーゼとを連結した人工ヌクレアーゼを用い、該特定配列の近傍で標的遺伝子を切断する方法(特許文献4)も報告されている。
しかしながら、DSBは想定外のゲノム改変を伴うため、強い細胞毒性や染色体の転位などの副作用があり、生存細胞数が極めて少なかったり、単細胞微生物では、そもそも遺伝子改変自体が困難であるといった課題があった。
そこで、このような核酸塩基の変換を行う酵素として脱アミノ化反応を触媒するデアミナーゼを用い、これとDNA配列認識能のある分子(核酸配列認識モジュール)とを複合体形成させることにより、3種のグラム陽性菌の特定DNA配列を含む領域における核酸塩基変換によるゲノム配列の改変を行った。
具体的には、CRISPR-Casシステム(CRISPR-変異Cas)を用いて行った。即ち、改変しようとする遺伝子の標的ヌクレオチド配列と相補的な配列(ターゲッティング配列)を含むゲノム特異的CRISPR-RNA(crRNA)に、Casタンパク質をリクルートするためのRNA(trans-activating crRNA : tracrRNA)を連結したキメラRNA分子(ガイドRNA)をコードするDNAを作製し、他方で二本鎖DNAの両方の鎖の切断能を失活した変異Casタンパク質をコードするDNA(dCas)とデアミナーゼ遺伝子とを連結したDNAを作製し、これらのDNAを、各宿主細胞で機能する発現ベクターを用いて、グラム陽性菌に導入した。その結果、標的ヌクレオチド配列内の目的の塩基を首尾よく他の塩基に置換することができた。
本発明者らは、これらの知見に基づいてさらに研究を重ねた結果、本発明を完成するに至った。
[1]グラム陽性菌の有する二本鎖DNAの標的化された部位を改変する方法であって、選択された二本鎖DNA中の標的ヌクレオチド配列と特異的に結合する核酸配列認識モジュールと、核酸塩基変換酵素とが結合した複合体を、該二本鎖DNAと接触させ、該標的化された部位において該二本鎖DNAの少なくとも一方の鎖を切断することなく、該標的化された部位の1以上のヌクレオチドを他の1以上のヌクレオチドに変換する又は欠失させる、あるいは該標的化された部位に1以上のヌクレオチドを挿入する工程を含み、該二本鎖DNAと該複合体との接触が、該グラム陽性菌への該複合体をコードする核酸の導入により行われる、方法。
[2]前記核酸配列認識モジュールが、Casの少なくとも1つのDNA切断能が失活したCRISPR-Casシステム、ジンクフィンガーモチーフ、TALエフェクター及びPPRモチーフからなる群より選択される、上記[1]記載の方法。
[3]前記核酸配列認識モジュールが、Casの少なくとも1つのDNA切断能が失活したCRISPR-Casシステムである、上記[1]記載の方法。
[4]異なる標的ヌクレオチド配列とそれぞれ特異的に結合する、2種以上の核酸配列認識モジュールを用いることを特徴とする、上記[1]~[3]のいずれかに記載の方法。
[5]前記異なる標的ヌクレオチド配列が、異なる遺伝子内に存在する、上記[4]記載の方法。
[6]前記核酸塩基変換酵素がデアミナーゼである、上記[1]~[5]のいずれかに記載の方法。
[7]前記デアミナーゼがシチジンデアミナーゼである、上記[6]記載の方法。
[8]前記グラム陽性菌がバチルス(Bacillus)属以外の微生物である、上記[1]~「7」のいずれかに記載の方法。
[9]前記グラム陽性菌がクロストリジウム(Clostridium)属、ブレビバチルス(Brevibacillus)属又はコリネバクテリウム(Corynebacterium)属に属する微生物である、上記[8]記載の方法。
[10]クロストリジウム属に属する微生物がクロストリジウム・サッカロパーブチルアセトニカム(Clostridium saccharoperbutylacetonicum)である、上記[9]記載の方法。
[11]ブレビバチルス属に属する微生物がブレビバチルス・チョウシネンシス(Brevibacillus chosinensis)である、上記[9]記載の方法。
[12]コリネバクテリウム属に属する微生物がコリネバクテリウム・グルタミカム(Corynebacterium glutamicum)である、上記[9]記載の方法。
[13]前記複合体をコードする核酸を、発現期間を制御可能な形態で含む発現ベクターを、前記グラム陽性菌に導入する工程、及び
二本鎖DNAの標的化された部位の改変が固定されるのに必要な期間、該核酸の発現を誘導する工程、
を含む、上記[1]~[12]のいずれかに記載の方法。
[14]グラム陽性菌の有する二本鎖DNA中の標的ヌクレオチド配列と特異的に結合する核酸配列認識モジュールと、核酸塩基変換酵素とが結合した複合体であって、標的化された部位において該二本鎖DNAの少なくとも一方の鎖を切断することなく、該標的化された部位の1以上のヌクレオチドを他の1以上のヌクレオチドに変換する又は欠失させる、あるいは該標的化された部位に1以上のヌクレオチドを挿入する、該グラム陽性菌で機能する核酸改変酵素複合体。
[15]上記[14]記載の核酸改変酵素複合体をコードする核酸。
従って、核酸配列認識モジュールと、核酸塩基変換酵素とは、それらの融合タンパク質をコードする核酸として、あるいは、結合ドメインやインテイン等を利用してタンパク質に翻訳後、宿主細胞内で複合体形成し得るような形態で、それらをそれぞれコードする核酸として調製される。ここで核酸は、DNAであってもRNAであってもよい。DNAの場合は、好ましくは二本鎖DNAであり、宿主細胞内で機能的なプロモーターの制御下に配置した発現ベクターの形態で提供される。RNAの場合は、好ましくは一本鎖RNAである。
核酸配列認識モジュールと核酸塩基変換酵素とが結合した本発明の複合体は、DNA二重鎖切断(DSB)を伴わないため、毒性の低いゲノム編集が可能であり、本発明の遺伝子改変方法は、広くグラム陽性菌全般に適用することができる。
核酸塩基変換酵素をコードするDNAも、同様に、使用する酵素のcDNA配列情報をもとにオリゴDNAプライマーを合成し、当該酵素を産生する細胞より調製した全RNAもしくはmRNA画分を鋳型として用い、RT-PCR法によって増幅することにより、クローニングすることができる。例えば、ヤツメウナギのPmCDA1をコードするDNAは、NCBIデータベースに登録されているcDNA配列(accession No. EF094822)をもとに、CDSの上流及び下流に対して適当なプライマーを設計し、ヤツメウナギ由来mRNAからRT-PCR法によりクローニングできる。また、ヒトAIDをコードするDNAは、NCBIデータベースに登録されているcDNA配列(accession No. AB040431)をもとに、CDSの上流及び下流に対して適当なプライマーを設計し、例えばヒトリンパ節由来mRNAからRT-PCR法によりクローニングできる。他の脊椎動物由来のAIDホモログも、公知のcDNA配列情報(例えば、ブタ(accession No. CU582981)、ウシ(accession No. NM_110138682)、イヌ(accession No. NM_001003380)、チンパンジー(accession No. NM_001071809)、ニワトリ(accession No. NM_001243222)、アフリカツメガエル(accession No. NM_001095712)、ゼブラフィッシュ(accession No. AAI62573)、アユ(accession No. AB619797)、ブチナマズ(accession No. NM_001200185)等)をもとに、上記と同様にしてクローニングすることができる。
クローン化されたDNAは、そのまま、または所望により制限酵素で消化するか、適当なリンカーを付加した後に、核酸配列認識モジュールをコードするDNAとライゲーションして、融合タンパク質をコードするDNAを調製することができる。あるいは、核酸配列認識モジュールをコードするDNAと、核酸塩基変換酵素をコードするDNAに、それぞれ結合ドメインもしくはその結合パートナーをコードするDNAを融合させるか、両DNAに分離インテインをコードするDNAを融合させることにより、核酸配列認識モジュールと核酸塩基変換酵素とが宿主細胞内で翻訳された後に複合体を形成できるようにしてもよい。これらの場合も、所望により一方もしくは両方のDNAの適当な位置に、リンカーを連結することができる。
例えば、クロストリジウム属で複製可能なベクターとしては、大腸菌とクロストリジウム属のシャトルベクターであれば都合がよく、例えば、pIM13由来のpKNT19(Journal of General Microbiology, 138, 1371-1378 (1992))、pJIR756、pNAK1が挙げられる。またブレビバチルス属で複製可能なベクターとしては、Brevibacillus brevis由来のpUB110、コリネバクテリウム属で複製可能なベクターとしては、Corynebacterium glutamicum由来のpCG100-pHSG398ハイブリッドプラスミドが挙げられる。さらに、ラクトバチルス属で複製可能なベクターとしては、Lactobacillus lactis由来のpLAB1000などが挙げられる。
プロモーターとしては、遺伝子の発現に用いる宿主に対応して適切なプロモーターであればいかなるものでもよい。DSBを伴う従来法では毒性のために宿主細胞の生存率が著しく低下する場合があるので、誘導プロモーターを使用して誘導開始までに細胞数を増やしておくことが望ましいが、本発明の核酸改変酵素複合体を発現させても十分な細胞増殖が得られるので、構成プロモーターも制限なく使用することができる。
グラム陽性菌の培養は、通常約30~約40℃で行なわれる。必要により、通気や撹拌を行ってもよい。
以上のようにして、核酸配列認識モジュールと核酸塩基変換酵素との複合体、即ち核酸改変酵素複合体を細胞内で発現させることができる。
これに対し、CRISPR-Casシステムは、標的ヌクレオチド配列に対して相補的なガイドRNAにより目的の二本鎖DNAの配列を認識するので、標的ヌクレオチド配列と特異的にハイブリッド形成し得るオリゴDNAを合成するだけで、任意の配列を標的化することができる。
従って、本発明のより好ましい実施態様においては、核酸配列認識モジュールとして、Casの少なくとも1つのDNA切断能が失活したCRISPR-Casシステム(CRISPR-変異Cas)が用いられる。
CasをコードするDNAは、核酸塩基変換酵素をコードするDNAについて上記したのと同様の方法により、該酵素を産生する細胞からクローニングすることができる。また、変異Casは、クローン化されたCasをコードするDNAに、自体公知の部位特異的変異誘発法を用いて、DNA切断活性に重要な部位のアミノ酸残基(例えば、Cas9の場合、10番目のAsp残基や840番目のHis残基が挙げられるが、これらに限定されない)を他のアミノ酸で変換するように変異を導入することにより、取得することができる。
あるいは変異CasをコードするDNAは、核酸配列認識モジュールをコードするDNAや核酸塩基変換酵素をコードするDNAについて上記したのと同様の方法により、化学合成又はPCR法もしくはGibson Assembly法との組み合わせで、用いる宿主細胞での発現に適したコドン使用を有するDNAとして構築することもできる。
得られた変異Cas及び/又は核酸塩基変換酵素をコードするDNAは、宿主に応じて、上記と同様の発現ベクターのプロモーターの下流に挿入することができる。
ここで「標的鎖」とは、標的ヌクレオチド配列のcrRNAとハイブリッド形成する方の鎖を意味し、その反対鎖で標的鎖とcrRNAとのハイブリッド形成により一本鎖状になる鎖を「非標的鎖(non-targeted strand)」と呼ぶこととする。また、核酸塩基変換反応は通常、一本鎖状になった非標的鎖上で起こる場合が多いと推定されるので、標的ヌクレオチド配列を片方の鎖で表現する場合(例えばPAM配列を表記する場合や、標的ヌクレオチド配列とPAMとの位置関係を表す場合等)、非標的鎖の配列で代表させるものとする。
ガイドRNA(crRNA-tracrRNA)は、標的ヌクレオチド配列の標的鎖に対して相補的な配列と既知のtracrRNA配列とを連結したオリゴRNA配列を設計し、DNA/RNA合成機を用いて、化学的に合成することができる。
尚、本発明の二本鎖DNAの改変では、標的化された部位(標的ヌクレオチド配列の全部もしくは一部を含む数百塩基の範囲内で適宜調節できる)以外で、該二本鎖DNAの切断が生じることを妨げない。しかしながら、本発明の最大の利点の1つが、オフターゲット切断による毒性を回避することであることを考慮すれば、好ましい一実施態様においては、本発明の二本鎖DNAの改変は、選択された二本鎖DNAの標的化された部位のみならず、それ以外の部位でのDNA鎖切断も伴わない。
また、変異導入効率が極めて高く、かつマーカーによる選抜を必要としないことから、本発明のゲノム配列の改変方法においては、全く異なる位置の複数のDNA領域を標的として改変することが可能である。従って、本発明の好ましい一実施態様においては、異なる標的ヌクレオチド配列(1つの目的遺伝子内であってもよいし、異なる2以上の目的遺伝子内にあってもよい。)とそれぞれ特異的に結合する、2種以上の核酸配列認識モジュールを用いることができる。この場合、これらの核酸配列認識モジュールの各々1つと、核酸塩基変換酵素とが、核酸改変酵素複合体を形成する。ここで核酸塩基変換酵素は共通のものを使用することができる。例えば、核酸配列認識モジュールとしてCRISPR-Casシステムを用いる場合、Casタンパク質と核酸塩基変換酵素との複合体(融合タンパク質を含む)は共通のものを用い、ガイドRNA(crRNA-tracrRNA)として、異なる標的ヌクレオチド配列とそれぞれ相補鎖を形成する2以上のcrRNAの各々と、tracrRNAとのキメラRNAを2種以上作製して用いることができる。一方、核酸配列認識モジュールとしてジンクフィンガーモチーフやTALエフェクターなどを用いる場合には、例えば、異なる標的ヌクレオチドと特異的に結合する各核酸配列認識モジュールに、核酸塩基変換酵素を融合させることができる。
あるいは、変異導入に十分な核酸改変酵素複合体の発現が得られる限り、宿主細胞内での自律複製能を有しない発現ベクター(例えば、宿主細胞で機能する複製起点及び/又は複製に必要なタンパク質をコードする遺伝子を欠くベクター等)や、RNAを用いて、一過的発現により目的の二本鎖DNAに変異を導入することもまた好ましい。
(1)破壊ベクタープラスミドの構築-pKNT19への改変CRISPRの導入
大腸菌とクロストリジウム属微生物で複製可能なプラスミドpKNT19の制限酵素BamHIとKpnIで切断される間に下記の必要な遺伝子配列を挿入して破壊ベクタープラスミドを構築した。
双方向プロモーター領域を含むStreptococcus pyogens Cas9遺伝子にD10A及びH840Aのアミノ酸変異を導入し(dCas9)、リンカー配列を介してPmCDA1との融合タンパク質として発現するコンストラクトを構築し、さらにC. サッカロパーブチルアセトニカムのpta遺伝子(配列番号2および3)内の各標的ヌクレオチド配列に相補的な配列(ターゲッティング配列)をコードしたキメラgRNAを同時に載せたプラスミド(全長ヌクレオチド配列を配列番号4に示す。配列中n20の部分(ヌクレオチド番号5560-5579)に各ターゲッティング配列が挿入される)を作成した(図1)。
上記(1)で作成した破壊ベクタープラスミドのうち、11757または1269+AatIIをC. サッカロパーブチルアセトニカムATCC27021株及びATCC27021Δptb1株(特開2014-207885の実施例1を参照)に形質転換した。破壊ベクタープラスミド11757、1269+AatIIのターゲッティング配列等を表1に示した。
前培養として、C. サッカロパーブチルアセトニカムATCC27021株及びATCC27021Δptb1株のグリセロールストック0.5 mLをTYA培地5 mLに接種し、30℃、24時間培養した。TYA培地の組成を表2に示す。
全てプラスミド特有の領域の増幅物が得られた。従ってブタノール発酵菌内で破壊ベクタープラスミドが保持されていることが明らかとなった。
破壊ベクタープラスミドを用い、ブタノール発酵菌のpta遺伝子のDNA配列変換を行った。破壊ベクタープラスミドは破壊ツールに制御機構を有しないため、単純に世代を重ねるのみで機能する。
上記(2)で作成した11757保持株である11757/ATCC27021Δptb1株、1269+AatII保持株である1269+AatII/ATCC27021Δptb1及び1269+AatII/ATCC27021株を、エリスロマイシン10 ppmを含有するTYA培地に植菌し培養した後、エリスロマイシン10 ppmを含有するTYA固体培地に希釈塗布し、シングルコロニーとした。このシングルコロニーを11757/ATCC27021Δptb1株及び1269+AatII/ATCC27021株では8コロニー、1269+AatII/ATCC27021Δptb1では16コロニー取り、これを鋳型にゲノム上のpta遺伝子全長の増幅を行った。
2×KODFX buffer 25 μL
2 mM dNTPS 10μL
20μM F primer 0.75 μL (NS-150414-i02)
20 μM R primer 0.75 μL (NS-150304-i04)
D.W. 11.5 μL
KODFX 1μL
5’-GCCCTTTATGAAAGGGATTATATTCAG-3’(配列番号7)
NS-150304-i04の配列
5’-GCTTGTACAGCAGTTAATGCAAC-3’(配列番号8)
94℃ 2 min
98℃ 10 sec → 50℃ 30 sec → 68℃ 2 min ×30 cycles
10℃ hold
Terminator Ready Reaction Mix 1 μL
5×Sequencing buffer 3.5 μL
3.2pmol primer 1 μL
Template DNA 0.35 μL
D.W. 14.15 μL
Template DNAとprimerは下記の組み合わせとした。
1269+AatII保持株
F側NS-150414-i02 / R側NS-150304-i04
11753保持株
F側NS-150525-i01 / R側NS-150304-i04
5’-GGTGTTACAGGAAATGTTGCAG-3’(配列番号9)
96℃ 1 min
96℃ 10 sec → 50℃ 5 sec → 60℃ 4 min ×25 cycles
10℃ hold
反応終了後に反応物の配列をDNAシーケンサーABI PRISM3101にて解析した。
11757/ATCC27021Δptb1由来コロニーの配列解析結果のうち、pta遺伝子のDNA配列の916~935番目を表3に示した。
(1)シャトルベクターの作製
WO 2007/013695の実施例1に記載された方法で、C. グルタミカム ATCC13058株由来のpCG100プラスミドを取得した。
pHSG398とのライゲーションを行うため、pCG100を制限酵素BglIIで切断処理し、pHSG398はBamHIで切断し、脱リン酸化処理してセルフライゲーションが起こらないようにした。pCG100(BglIIで切断)とpHSG398(BamHIで切断)をライゲーションし、大腸菌に導入した。
改変CRISPRのDNA断片(配列番号18のHindIII-XhoI約6 kbp断片)の両末端にPstI部位を付加し、これをpCG100-pHSG398プラスミドをPstIで切断した場所に挿入して、C. グルタミカムで機能する改変CRISPRプラスミドを作製した。C. グルタミカムのpknG遺伝子(配列番号19及び20)を改変するためのターゲッティング配列(表6)をデザインし、そのうちNo. 6、7、8及び10を、この改変CRISPRプラスミドのターゲッティング配列挿入部位(n20)(配列番号18のヌクレオチド番号8773-8492)に挿入し、pknG遺伝子改変プラスミドを作製した。
WO 2007/013695の実施例2に記載された方法で、C.グルタミカム ATCC13032株に(2)で作製したpknG遺伝子改変プラスミドを導入した。形質転換後にLBCm60ppm寒天培地でコロニーを形成させた。このコロニーをLBCm60ppm液体培地に接種して2回植え継ぎ培養した後、希釈してLB寒天培地でコロニーを形成させた。
生育したコロニーをLB培地で培養し、下記プライマーを用いてpknG遺伝子断片をPCRで増幅し、その配列を解析したところ、推測された位置に終止コドンが導入されていることを確認することができた。
PCRプライマーF atgaaggataatgaagatttcgatccagattcac(配列番号41)
PCRプライマーR gaaccaactcagtggccgc(配列番号42)
また、表6に記載の他のターゲッティング配列を、上記(2)の改変CRISPRプラスミドのターゲッティング配列挿入部位に挿入したpknG遺伝子改変プラスミドを作製し、上記(3)と同様の方法で、C.グルタミカム ATCC13032株を形質転換し、コロニーを形成させた。
生育したコロニーをLB培地で培養し、下記プライマーを用いてpknG遺伝子断片をPCRで増幅し、その配列を解析したところ、No. 2のターゲッティング配列を用いた場合に、203番目のCがTに変わり、終始コドン形成ではなかったが、コードするアミノ酸がスレオニンからイソロイシンに変わった株を得ることができた。
PCRプライマーF cagcaaccgaagctgttgcc(配列番号72)
PCRプライマーR gccatcagcaactgggcg(配列番号73)
(1)emp遺伝子改変プラスミドの作製
B. チョウシネンシスで使用可能なpBIC1プラスミドを制限酵素XhoIとHindIIIで切断し、その間に必要な改変CRISPRのDNA断片(上述の配列番号18のHindIII-XhoI約6 kbp断片)を挿入し、B. チョウシネンシスを形質転換して機能する改変CRISPRプラスミドを作製した。B. チョウシネンシスのemp遺伝子(配列番号43及び44)を改変するためのターゲッティング配列(表7)をデザインし、そのうちNo. 5、6および7を、この改変CRISPRプラスミドのターゲッティング配列挿入部位(n20)(配列番号18のヌクレオチド番号8773-8792)に挿入し、emp遺伝子改変プラスミドを作製した。
B. チョウシネンシスの形質転換はTAKARA Brevibacillus Expression system HB300に基づいて行った。形質転換後にMTNm 50 ppmプレートでコロニーを形成させた。コロニーをMTNm 50 ppm液体培地に接種して2回植え継ぎ培養した後、希釈してMTプレートでコロニーを形成させた。
・培地
MTNmプレート
MT培地にネオマイシン50 ppmになるように添加
MT培地
グルコース 10 g/L
ファイトンペプトン 10 g/L
エルリッヒ カツオエキス 5 g/L
粉末酵母エキスS 2 g/L
FeSO4・7H2O 10 mg/L
MnSO4・4H2O 10 mg/L
ZnSO4・7H2O 1 mg/L
pH 7.0に調節
PCRプライマーF gggacatgattcgccggttg(配列番号59)
PCRプライマーR gcgtccatcgtagtaccagatc(配列番号60)
また、表7に記載の他のターゲッティング配列を、上記(1)の改変CRISPRプラスミドのターゲッティング配列挿入部位に挿入したemp遺伝子改変プラスミドを作製し、上記(2)と同様の方法で、B. チョウシネンシスを形質転換し、コロニーを形成させた。
生育したコロニーをMT液体培地で培養し、下記プライマーを用いてemp遺伝子断片をPCRで増幅し、その配列を解析したところ、No. 3のターゲッティング配列を用いた場合に、454番目のCがTに変わり、それに伴いグルタミンから終止コドンに変わった株を得ることができた。
PCRプライマーF ccggaagccatacaggtaagatc(配列番号74)
PCRプライマーR cctgagtcgacatcaatcacgttc(配列番号75)
(1)複数遺伝子破壊用宿主の作成
実施例1(2)で作成した11757保持株である11757/ATCC27021を用いて、ATCC27021株のpta遺伝子のDNA配列変換を行った。次に、複数の遺伝子が破壊された株の作成のため、得られた変異株R311K(pta遺伝子の932番目の塩基GがAに改変)及びG312R(pta遺伝子の934番目の塩基GがAに改変)からプラスミド11757を除去した。
実施例1(2)で作成した11757保持株である11757/ATCC27021を用いて、実施例1(3)と同様の方法でpta遺伝子のDNA配列変換及び配列解析を行った。配列解析の結果得られた変異株R311K(pta遺伝子の932番目の塩基GがAに改変)及びG312R(pta遺伝子の934番目の塩基GがAに改変)株を、抗生物質を含まないTYA培地で培養した後、固形培地に希釈塗布し、生育したシングルコロニーを鋳型に、実施例1(2)に示した方法でプラスミド保持の有無を確認し、プラスミド特有の領域の増幅物が無いコロニーを選抜した。
2×KODFX buffer 25 μL
2 mM dNTPS 10μL
20 μM F primer 0.75 μL (NS-150410-i01)
20 μM R primer 0.75 μL (NS-150410-i02)
D.W. 11.5 μL
KODFX 1μL
5’-CCGATAGCTAAGCCTATTGAG-3’(配列番号61)
NS-150410-i02の配列
5’-TCATCCTGTGGAGCTTAGTAG-3’(配列番号62)
94℃ 2 min
98℃ 10 sec → 50℃ 30 sec → 68℃ 2 min ×30 cycles
10℃ hold
得られたPCR産物を電気泳動し、各変異株(R311K及びG312R)由来の、プラスミド特有の領域の増幅物が無いコロニーを、それぞれ11757脱落株ATCC27021R311K及びATCC27021G312Rとした。
実施例1(1)で作成した破壊ベクタープラスミドのターゲッティング配列部分[配列番号4で表されるヌクレオチド配列中n20の部分(ヌクレオチド番号5560-5579);図1の「Target」に相当]を、C. サッカロパーブチルアセトニカムのptb1遺伝子(配列番号63および64)内の各標的ヌクレオチド配列に相補的な配列に置換した、4種のptb1破壊ベクタープラスミド64G>A、655G>A、442C>Tおよび745G>Aを構築した。これらの破壊ベクタープラスミドのターゲッティング配列等を表8に示した。
上記のptb1破壊ベクタープラスミド64G>A、442C>T、655G>Aまたは745G>Aで、C. サッカロパーブチルアセトニカムATCC27021株、並びに上記(1)で作成したATCC27021R311K及びATCC27021G312株を形質転換した。破壊ベクタープラスミドの導入とプラスミド保持の確認は、実施例1(2)に示した方法で行った。
得られた株を鋳型にしたプラスミド保持確認PCRの結果、全ての宿主においてプラスミド特有の領域の増幅物が得られ、形質転換体と確認された。
破壊ベクタープラスミドを用い、ブタノール発酵菌のptb1遺伝子のDNA配列変換を行った。
上記(2)で作成した64G>A保持株である64G>A/ATCC27021株、64G>A/ATCC27021R312K株及び64G>A/ATCC27021G312株、442C>T保持株である442C>T/ATCC27021株、442C>T/ATCC27021R311K株及び442C>T/ATCC27021G312株、655G>A保持株である655G>A/ATCC27021株、655G>A/ATCC27021R311K株及び655G>A/ATCC27021G312R株、745G>A保持株である745G>A/ATCC27021株、745G>A/ATCC27021R311K株及び745G>A/ATCC27021G312R株を、エリスロマイシン10 ppmを含有するTYA培地に植菌し培養した後、エリスロマイシン10 ppmを含有するTYA固体培地に希釈塗布し、シングルコロニーとした。このシングルコロニーを取り、これを鋳型にゲノム上のptb1遺伝子全長の増幅を行った。
PCR組成、条件は実施例1(3)に従い、プライマーのみptb1用のNS-150819-i01及びNS-150819-i02を用いた。
5’-GCAAGAAATGAGCAAAAACTTTGACG-3’(配列番号69)
NS-150819-i02の配列
5’-GCTGCAACTAATGCTGCTAAAGC-3’ (配列番号70)
シーケンス反応組成、条件は実施例1(3)に従い、プライマーのみ64G>A保持株についてはNS-150819-i01(配列番号69)、その他はNS-150324-i01を用いた。
5’-CTCTGACTGTGCAGTTAACC-3’ (配列番号71)
64G>A保持株由来コロニーの配列解析の結果、ptb1遺伝子内に64G>Aおよび/または67G>Aの変異導入のある株が得られた。64G>Aおよび/または67G>Aの変異により、PTB1タンパク質としてV22Iおよび/またはA23Tとなった株が得られた。V22M変異が導入された株は今回の解析では無かった。442C>T保持株由来コロニーの配列解析の結果、442C>Tおよび/または443C>Tの変異導入のある株が得られた。442C>Tおよび/または443C>Tの変異により、PTB1タンパク質としてP148LまたはP148Sとなった株が得られた。655G>A保持株由来コロニーの配列解析の結果、655G>Aの変異導入のある株が得られた。655G>Aの変異により、PTB1タンパク質としてA219Tとなった株が得られた。745G>A保持株由来コロニーの配列解析の結果、745G>Aおよび/または751G>Aの変異導入のある株が得られた。745G>Aおよび/または751G>Aの変異により、PTB1タンパク質としてA249Tおよび/またはV251Iとなった株が得られた。
Claims (15)
- グラム陽性菌の有する二本鎖DNAの標的化された部位を改変する方法であって、選択された二本鎖DNA中の標的ヌクレオチド配列と特異的に結合する核酸配列認識モジュールと、核酸塩基変換酵素とが結合した複合体を、該二本鎖DNAと接触させ、該標的化された部位において該二本鎖DNAの少なくとも一方の鎖を切断することなく、該標的化された部位の1以上のヌクレオチドを他の1以上のヌクレオチドに変換する又は欠失させる、あるいは該標的化された部位に1以上のヌクレオチドを挿入する工程を含み、該二本鎖DNAと該複合体との接触が、該グラム陽性菌への該複合体をコードする核酸の導入により行われる、方法。
- 前記核酸配列認識モジュールが、Casの少なくとも1つのDNA切断能が失活したCRISPR-Casシステム、ジンクフィンガーモチーフ、TALエフェクター及びPPRモチーフからなる群より選択される、請求項1記載の方法。
- 前記核酸配列認識モジュールが、Casの少なくとも1つのDNA切断能が失活したCRISPR-Casシステムである、請求項1記載の方法。
- 異なる標的ヌクレオチド配列とそれぞれ特異的に結合する、2種以上の核酸配列認識モジュールを用いることを特徴とする、請求項1~3のいずれか1項に記載の方法。
- 前記異なる標的ヌクレオチド配列が、異なる遺伝子内に存在する、請求項4記載の方法。
- 前記核酸塩基変換酵素がデアミナーゼである、請求項1~5のいずれか1項に記載の方法。
- 前記デアミナーゼがシチジンデアミナーゼである、請求項6記載の方法。
- 前記グラム陽性菌がバチルス(Bacillus)属以外の微生物である、請求項1~7のいずれか1項に記載の方法。
- 前記グラム陽性菌がクロストリジウム(Clostridium)属、ブレビバチルス(Brevibacillus)属又はコリネバクテリウム(Corynebacterium)属に属する微生物である、請求項8記載の方法。
- クロストリジウム属に属する微生物がクロストリジウム・サッカロパーブチルアセトニカム(Clostridium saccharoperbutylacetonicum)である、請求項9記載の方法。
- ブレビバチルス属に属する微生物がブレビバチルス・チョウシネンシス(Brevibacillus chosinensis)である、請求項9記載の方法。
- コリネバクテリウム属に属する微生物がコリネバクテリウム・グルタミカム(Corynebacterium glutamicum)である、請求項9記載の方法。
- 前記複合体をコードする核酸を、発現期間を制御可能な形態で含む発現ベクターを、前記グラム陽性菌に導入する工程、及び
二本鎖DNAの標的化された部位の改変が固定されるのに必要な期間、該核酸の発現を誘導する工程、
を含む、請求項1~12のいずれか1項に記載の方法。 - グラム陽性菌の有する二本鎖DNA中の標的ヌクレオチド配列と特異的に結合する核酸配列認識モジュールと、核酸塩基変換酵素とが結合した複合体であって、標的化された部位において該二本鎖DNAの少なくとも一方の鎖を切断することなく、該標的化された部位の1以上のヌクレオチドを他の1以上のヌクレオチドに変換する又は欠失させる、あるいは該標的化された部位に1以上のヌクレオチドを挿入する、該グラム陽性菌で機能する核酸改変酵素複合体。
- 請求項14記載の核酸改変酵素複合体をコードする核酸。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BR112018004636-1A BR112018004636A2 (ja) | 2015-09-09 | 2016-09-09 | The converting method of the genome sequence of gram positive bacteria which changes the nucleic acid base of the targeted DNA arrangement specifically, and the molecule complex used for it |
ES16844517T ES2938623T3 (es) | 2015-09-09 | 2016-09-09 | Método para convertir una secuencia del genoma de una bacteria gram-positiva mediante una conversión específica de una base de ácido nucleico de una secuencia de ADN seleccionada como diana y el complejo molecular utilizado en el mismo |
DK16844517.9T DK3348638T3 (da) | 2015-09-09 | 2016-09-09 | Fremgangsmåde til at konvertere genomsekvens fra gram-positiv bakterie ved specifikt at konvertere nukleinsyrebase i tilsigtet dna-sekvens, og molekylkompleks anvendt dertil |
CN201680065297.7A CN108271384B (zh) | 2015-09-09 | 2016-09-09 | 用于特异性转变靶向dna序列的核酸碱基的革兰氏阳性菌的基因组序列的转变方法、及其使用的分子复合体 |
US15/757,243 US10767173B2 (en) | 2015-09-09 | 2016-09-09 | Method for converting genome sequence of gram-positive bacterium by specifically converting nucleic acid base of targeted DNA sequence, and molecular complex used in same |
JP2017538558A JP6664693B2 (ja) | 2015-09-09 | 2016-09-09 | 標的化したdna配列の核酸塩基を特異的に変換する、グラム陽性菌のゲノム配列の変換方法、及びそれに用いる分子複合体 |
EP16844517.9A EP3348638B1 (en) | 2015-09-09 | 2016-09-09 | Method for converting genome sequence of gram-positive bacterium by specifically converting nucleic acid base of targeted dna sequence, and molecular complex used in same |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015-178022 | 2015-09-09 | ||
JP2015178022 | 2015-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2017043656A1 true WO2017043656A1 (ja) | 2017-03-16 |
Family
ID=58239975
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2016/076711 WO2017043656A1 (ja) | 2015-09-09 | 2016-09-09 | 標的化したdna配列の核酸塩基を特異的に変換する、グラム陽性菌のゲノム配列の変換方法、及びそれに用いる分子複合体 |
Country Status (9)
Country | Link |
---|---|
US (1) | US10767173B2 (ja) |
EP (1) | EP3348638B1 (ja) |
JP (1) | JP6664693B2 (ja) |
CN (1) | CN108271384B (ja) |
BR (1) | BR112018004636A2 (ja) |
DK (1) | DK3348638T3 (ja) |
ES (1) | ES2938623T3 (ja) |
HK (1) | HK1253544A1 (ja) |
WO (1) | WO2017043656A1 (ja) |
Cited By (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10150974B2 (en) | 2013-06-28 | 2018-12-11 | Green Biologics Limited | Solvent production |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
JP2020022378A (ja) * | 2018-08-06 | 2020-02-13 | 株式会社日本触媒 | 遺伝子改変クロストリジウム・サッカロパーブチルアセトニカム種微生物 |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
CN111148833A (zh) * | 2018-03-26 | 2020-05-12 | 国立大学法人神户大学 | 改变细胞具有的双链dna的目标部位的方法 |
US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2914623T3 (es) | 2015-11-27 | 2022-06-14 | Univ Kobe Nat Univ Corp | Método para convertir una secuencia genómica de una planta monocotiledónea en la que una base de ácido nucleico en la secuencia de ADN diana se convierte de manera específica y el complejo molecular utilizado en el mismo |
SG11201809242VA (en) * | 2016-04-21 | 2018-11-29 | Univ Kobe Nat Univ Corp | Method for increasing mutation introduction efficiency in genome sequence modification technique, and molecular complex to be used therefor |
MX2021001525A (es) * | 2018-08-07 | 2021-04-19 | Modalis Therapeutics Corp | Activador novedoso de la transcripcion. |
CN110343689B (zh) * | 2019-08-23 | 2021-11-05 | 四川大学 | 一种链霉菌胰蛋白酶gm2938及其在枯草芽孢杆菌中的异源表达 |
US20220333133A1 (en) | 2019-09-03 | 2022-10-20 | Voyager Therapeutics, Inc. | Vectorized editing of nucleic acids to correct overt mutations |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110104787A1 (en) * | 2009-11-05 | 2011-05-05 | President And Fellows Of Harvard College | Fusion Peptides That Bind to and Modify Target Nucleic Acid Sequences |
JP2013513389A (ja) * | 2009-12-10 | 2013-04-22 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Talエフェクターに媒介されるdna修飾 |
JP2015510772A (ja) * | 2012-03-23 | 2015-04-13 | セレクティスCellectis | 工学的に操作されたtaledna結合性ドメインの化学的dna改変感受性を変更する方法 |
WO2015089406A1 (en) * | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Cas variants for gene editing |
JP2015523856A (ja) * | 2012-05-25 | 2015-08-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフ | Rna依存性標的dna修飾およびrna依存性転写調節のための方法および組成物 |
WO2015133554A1 (ja) * | 2014-03-05 | 2015-09-11 | 国立大学法人神戸大学 | 標的化したdna配列の核酸塩基を特異的に変換するゲノム配列の改変方法及びそれに用いる分子複合体 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8106255B2 (en) | 2002-01-23 | 2012-01-31 | Dana Carroll | Targeted chromosomal mutagenasis using zinc finger nucleases |
CN104531672B (zh) | 2007-03-02 | 2020-01-10 | 杜邦营养生物科学有限公司 | 具有改善的噬菌体抗性的培养物 |
WO2010132092A2 (en) | 2009-05-12 | 2010-11-18 | The Scripps Research Institute | Cytidine deaminase fusions and related methods |
JP2013128413A (ja) | 2010-03-11 | 2013-07-04 | Kyushu Univ | Pprモチーフを利用したrna結合性蛋白質の改変方法 |
WO2013058404A1 (ja) | 2011-10-21 | 2013-04-25 | 国立大学法人九州大学 | Pprモチーフを利用したrna結合性蛋白質の設計方法及びその利用 |
GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
CA2871524C (en) * | 2012-05-07 | 2021-07-27 | Sangamo Biosciences, Inc. | Methods and compositions for nuclease-mediated targeted integration of transgenes |
US20150315576A1 (en) | 2012-11-01 | 2015-11-05 | Massachusetts Institute Of Technology | Genetic device for the controlled destruction of dna |
PT2896697E (pt) | 2012-12-12 | 2015-12-31 | Massachusetts Inst Technology | Engenharia de sistemas, métodos e composições guia otimizadas para a manipulação de sequências |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
CN110982844B (zh) | 2012-12-12 | 2024-08-13 | 布罗德研究所有限公司 | 用于序列操纵的crispr-cas组分系统、方法以及组合物 |
EP2981166B1 (en) | 2013-04-05 | 2020-09-09 | Dow AgroSciences LLC | Methods and compositions for integration of an exogenous sequence within the genome of plants |
US11414695B2 (en) | 2013-05-29 | 2022-08-16 | Agilent Technologies, Inc. | Nucleic acid enrichment using Cas9 |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
PT3216867T (pt) | 2014-11-04 | 2020-07-16 | Univ Kobe Nat Univ Corp | Método para modificar a sequência de genoma para introduzir mutação específica a sequência de adn alvo por reação de remoção de bases, e complexo molecular nele utilizado |
DK3348636T3 (da) | 2015-09-09 | 2022-02-28 | Univ Kobe Nat Univ Corp | Fremgangsmåde til modificering af en genomsekvens, der specifikt omdanner nukleobasen af en targetteret DNA-sekvens, og molekylær sekvens anvendt i fremgangsmåden |
AU2016342380B2 (en) | 2015-10-23 | 2022-04-07 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
ES2914623T3 (es) | 2015-11-27 | 2022-06-14 | Univ Kobe Nat Univ Corp | Método para convertir una secuencia genómica de una planta monocotiledónea en la que una base de ácido nucleico en la secuencia de ADN diana se convierte de manera específica y el complejo molecular utilizado en el mismo |
-
2016
- 2016-09-09 US US15/757,243 patent/US10767173B2/en active Active
- 2016-09-09 DK DK16844517.9T patent/DK3348638T3/da active
- 2016-09-09 WO PCT/JP2016/076711 patent/WO2017043656A1/ja active Application Filing
- 2016-09-09 CN CN201680065297.7A patent/CN108271384B/zh not_active Expired - Fee Related
- 2016-09-09 BR BR112018004636-1A patent/BR112018004636A2/ja active Search and Examination
- 2016-09-09 JP JP2017538558A patent/JP6664693B2/ja active Active
- 2016-09-09 ES ES16844517T patent/ES2938623T3/es active Active
- 2016-09-09 EP EP16844517.9A patent/EP3348638B1/en active Active
-
2018
- 2018-10-08 HK HK18112746.2A patent/HK1253544A1/zh unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20110104787A1 (en) * | 2009-11-05 | 2011-05-05 | President And Fellows Of Harvard College | Fusion Peptides That Bind to and Modify Target Nucleic Acid Sequences |
JP2013513389A (ja) * | 2009-12-10 | 2013-04-22 | リージェンツ オブ ザ ユニバーシティ オブ ミネソタ | Talエフェクターに媒介されるdna修飾 |
JP2015510772A (ja) * | 2012-03-23 | 2015-04-13 | セレクティスCellectis | 工学的に操作されたtaledna結合性ドメインの化学的dna改変感受性を変更する方法 |
JP2015523856A (ja) * | 2012-05-25 | 2015-08-20 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフ | Rna依存性標的dna修飾およびrna依存性転写調節のための方法および組成物 |
WO2015089406A1 (en) * | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Cas variants for gene editing |
WO2015133554A1 (ja) * | 2014-03-05 | 2015-09-11 | 国立大学法人神戸大学 | 標的化したdna配列の核酸塩基を特異的に変換するゲノム配列の改変方法及びそれに用いる分子複合体 |
Non-Patent Citations (3)
Title |
---|
KOMOR,A.C. ET AL.: "Programmable editing of a target base in genomic DNA without double- stranded DNA cleavage", NATURE, vol. 533, 20 April 2016 (2016-04-20), pages 420 - 424, XP055343871, DOI: doi:10.1038/nature17946 * |
NISHIDA,K. ET AL.: "Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems", SCIENCE, vol. 353, 4 August 2016 (2016-08-04), XP055367833, DOI: doi:10.1126/science.aaf8729 * |
See also references of EP3348638A4 * |
Cited By (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10323236B2 (en) | 2011-07-22 | 2019-06-18 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US12006520B2 (en) | 2011-07-22 | 2024-06-11 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
US10150974B2 (en) | 2013-06-28 | 2018-12-11 | Green Biologics Limited | Solvent production |
US10508298B2 (en) | 2013-08-09 | 2019-12-17 | President And Fellows Of Harvard College | Methods for identifying a target site of a CAS9 nuclease |
US11920181B2 (en) | 2013-08-09 | 2024-03-05 | President And Fellows Of Harvard College | Nuclease profiling system |
US10954548B2 (en) | 2013-08-09 | 2021-03-23 | President And Fellows Of Harvard College | Nuclease profiling system |
US11046948B2 (en) | 2013-08-22 | 2021-06-29 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
US10858639B2 (en) | 2013-09-06 | 2020-12-08 | President And Fellows Of Harvard College | CAS9 variants and uses thereof |
US11299755B2 (en) | 2013-09-06 | 2022-04-12 | President And Fellows Of Harvard College | Switchable CAS9 nucleases and uses thereof |
US10597679B2 (en) | 2013-09-06 | 2020-03-24 | President And Fellows Of Harvard College | Switchable Cas9 nucleases and uses thereof |
US10682410B2 (en) | 2013-09-06 | 2020-06-16 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US10912833B2 (en) | 2013-09-06 | 2021-02-09 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US9999671B2 (en) | 2013-09-06 | 2018-06-19 | President And Fellows Of Harvard College | Delivery of negatively charged proteins using cationic lipids |
US11124782B2 (en) | 2013-12-12 | 2021-09-21 | President And Fellows Of Harvard College | Cas variants for gene editing |
US10465176B2 (en) | 2013-12-12 | 2019-11-05 | President And Fellows Of Harvard College | Cas variants for gene editing |
US11053481B2 (en) | 2013-12-12 | 2021-07-06 | President And Fellows Of Harvard College | Fusions of Cas9 domains and nucleic acid-editing domains |
US11578343B2 (en) | 2014-07-30 | 2023-02-14 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10704062B2 (en) | 2014-07-30 | 2020-07-07 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
US10167457B2 (en) | 2015-10-23 | 2019-01-01 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US11214780B2 (en) | 2015-10-23 | 2022-01-04 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
US12043852B2 (en) | 2015-10-23 | 2024-07-23 | President And Fellows Of Harvard College | Evolved Cas9 proteins for gene editing |
US11999947B2 (en) | 2016-08-03 | 2024-06-04 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10113163B2 (en) | 2016-08-03 | 2018-10-30 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11702651B2 (en) | 2016-08-03 | 2023-07-18 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US10947530B2 (en) | 2016-08-03 | 2021-03-16 | President And Fellows Of Harvard College | Adenosine nucleobase editors and uses thereof |
US11661590B2 (en) | 2016-08-09 | 2023-05-30 | President And Fellows Of Harvard College | Programmable CAS9-recombinase fusion proteins and uses thereof |
US12084663B2 (en) | 2016-08-24 | 2024-09-10 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US11306324B2 (en) | 2016-10-14 | 2022-04-19 | President And Fellows Of Harvard College | AAV delivery of nucleobase editors |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
US11820969B2 (en) | 2016-12-23 | 2023-11-21 | President And Fellows Of Harvard College | Editing of CCR2 receptor gene to protect against HIV infection |
US11898179B2 (en) | 2017-03-09 | 2024-02-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
US11542496B2 (en) | 2017-03-10 | 2023-01-03 | President And Fellows Of Harvard College | Cytosine to guanine base editor |
US11268082B2 (en) | 2017-03-23 | 2022-03-08 | President And Fellows Of Harvard College | Nucleobase editors comprising nucleic acid programmable DNA binding proteins |
US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
US11732274B2 (en) | 2017-07-28 | 2023-08-22 | President And Fellows Of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE) |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11932884B2 (en) | 2017-08-30 | 2024-03-19 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
US11795443B2 (en) | 2017-10-16 | 2023-10-24 | The Broad Institute, Inc. | Uses of adenosine base editors |
CN111148833A (zh) * | 2018-03-26 | 2020-05-12 | 国立大学法人神户大学 | 改变细胞具有的双链dna的目标部位的方法 |
CN111148833B (zh) * | 2018-03-26 | 2021-04-02 | 国立大学法人神户大学 | 改变细胞具有的双链dna的目标部位的方法 |
US11041169B2 (en) | 2018-03-26 | 2021-06-22 | National University Corporation Kobe University | Method for modifying target site in double-stranded DNA in cell |
JP7126403B2 (ja) | 2018-08-06 | 2022-08-26 | 株式会社日本触媒 | 遺伝子改変クロストリジウム・サッカロパーブチルアセトニカム種微生物 |
JP2020022378A (ja) * | 2018-08-06 | 2020-02-13 | 株式会社日本触媒 | 遺伝子改変クロストリジウム・サッカロパーブチルアセトニカム種微生物 |
US11795452B2 (en) | 2019-03-19 | 2023-10-24 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11643652B2 (en) | 2019-03-19 | 2023-05-09 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11447770B1 (en) | 2019-03-19 | 2022-09-20 | The Broad Institute, Inc. | Methods and compositions for prime editing nucleotide sequences |
US11912985B2 (en) | 2020-05-08 | 2024-02-27 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
US12031126B2 (en) | 2020-05-08 | 2024-07-09 | The Broad Institute, Inc. | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
Also Published As
Publication number | Publication date |
---|---|
EP3348638A4 (en) | 2019-03-13 |
EP3348638B1 (en) | 2022-12-14 |
JP6664693B2 (ja) | 2020-03-13 |
CN108271384A (zh) | 2018-07-10 |
ES2938623T3 (es) | 2023-04-13 |
DK3348638T3 (da) | 2023-02-13 |
HK1253544A1 (zh) | 2019-06-21 |
EP3348638A1 (en) | 2018-07-18 |
US10767173B2 (en) | 2020-09-08 |
US20190203198A1 (en) | 2019-07-04 |
JPWO2017043656A1 (ja) | 2018-06-21 |
BR112018004636A2 (ja) | 2018-10-30 |
CN108271384B (zh) | 2022-04-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2017043656A1 (ja) | 標的化したdna配列の核酸塩基を特異的に変換する、グラム陽性菌のゲノム配列の変換方法、及びそれに用いる分子複合体 | |
JP7502537B2 (ja) | Ruvcドメインを有する酵素 | |
JP2022123889A (ja) | 標的化したdna配列の核酸塩基を特異的に変換するゲノム配列の改変方法及びそれに用いる分子複合体 | |
US10913941B2 (en) | Enzymes with RuvC domains | |
JP7328695B2 (ja) | 安定で副作用の少ないゲノム編集用複合体及びそれをコードする核酸 | |
JP7546689B2 (ja) | クラス2のii型crisprシステム | |
CA3177828A1 (en) | Enzymes with ruvc domains | |
JP2023540797A (ja) | 塩基編集酵素 | |
KR20240055073A (ko) | 클래스 ii, v형 crispr 시스템 | |
WO2021108501A1 (en) | System and method for activating gene expression | |
US20220220460A1 (en) | Enzymes with ruvc domains | |
CN113774077A (zh) | 一种应用于结核分枝杆菌的单碱基基因编辑系统及方法 | |
JP7250349B2 (ja) | 細胞の有する二本鎖dnaの標的部位を改変する方法 | |
KR20180111680A (ko) | CRISPR/Cas 시스템과 재조합 효소 및 단일가닥 올리고디옥시리보핵산을 이용한 코리네박테리움 변이균주 제조방법 | |
NZ548685A (en) | Reduction of spontaneous mutation rates in cells | |
JP2017051185A (ja) | ゲノム配列が特異的に変換された遺伝子改変クロストリジウム・サッカロパーブチルアセトニカム種微生物、その製造方法およびその用途 | |
JP7125727B1 (ja) | 核酸配列改変用組成物および核酸配列の標的部位を改変する方法 | |
Zh et al. | Design and study on characteristics of auto-and smoothly regulated genetic element O3/PlacUV5/Olac→ lacI | |
Yosef et al. | Using the CRISPR-cas system to positively select mutants in genes essential for its function | |
GB2617659A (en) | Enzymes with RUVC domains | |
HU215259B (hu) | Eljárás új klónozó és expressziós vektorok, ezeket tartalmazó gram-negatív baktériumok és ezek által termelt fehérjék előállítására | |
JP2005245261A (ja) | 変異型耐熱性ハイグロマイシンホスホトランスフェラーゼ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 16844517 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017538558 Country of ref document: JP Kind code of ref document: A |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112018004636 Country of ref document: BR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2016844517 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 112018004636 Country of ref document: BR Kind code of ref document: A2 Effective date: 20180308 |